CURRICULUM VITAE Elliott Richelson, M.D. EDUCATION: 06/65: B.A.; Brandeis University, Waltham, Massachusetts

06/69: M.D.; The Johns Hopkins University School of Medicine, Baltimore, Maryland TRAINING: 07/69-06/70: Internship in Medicine, Barnes Hospital, Washington University, St. Louis, Missouri 7/70-6/72: Research Associate, U.S. Public Health Service, Laboratory of Biochemical Genetics, National Heart and

Lung Institute, Bethesda, Maryland 07/72-06/75: Assistant Resident and Fellow, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins

University School of Medicine, Baltimore, Maryland APPOINTMENTS AND EMPLOYMENT: 07/72-06/75: Assistant Professor, Department of Pharmacology and Experimental Therapeutics, The Johns Hopkins

University School of Medicine, Baltimore, Maryland 07/75-06/88: Consultant in Psychiatry and Pharmacology, Mayo Clinic Rochester 07/75-06/78: Assistant Professor of Psychiatry and Pharmacology, Mayo Medical School, Rochester, Minnesota 07/78-06/81: Associate Professor of Psychiatry and Pharmacology, Mayo Medical School, Rochester, Minnesota 07/81-12/14 Professor of Psychiatry and Pharmacology, Mayo Medical School, Rochester, Minnesota 04/1988-07/95 Director for Research, Mayo Clinic Jacksonville 07/88-12/31/14 Consultant in Psychiatry and Pharmacology, Mayo Clinic Jacksonville 6/14-7/14 Adjunct Professor, Department of Psychiatry, University of Florida, Gainesville, Florida 12/2014 Retirement from Mayo Clinic Florida 01/15-2/19 Staff psychiatrist, Marsh Landing Behavioral Group, Jacksonville Beach, Florida 06/15-06/18 Consultant (Supplemental), Department of Psychiatry and Psychology, Mayo Clinic Florida 02/19-present Staff Psychiatrist, Comprehensive MedPsych Systems, Jacksonville Beach, Florida HONORS AND OTHER SPECIAL SCIENTIFIC RECOGNITION: 1964-65: Full tuition scholarship to Brandeis University awarded by Alumni of Middlesex University to outstanding

premedical student 1965: Brandeis University's Lewis S. Greenberg Memorial Award in Science 1965: Graduated from Brandeis University cum laude with honors in Chemistry 1968: First Prize, Medical Student Essay Contest in Pharmacology sponsored by the American Society for

Pharmacology and Experimental Therapeutics 1968: Scholar of the Henry Strong Denison Fund for Medical Research, The Johns Hopkins University School

of Medicine 1969: The Borden Undergraduate Research Award in Medicine, The Johns Hopkins University School of

Medicine 1974: Research Scientist Development Award (Type II), National Institute of Mental Health at Johns Hopkins

University 1977: A. E. Bennett Basic Science Research Award of the Society of Biological Psychiatry 1985: Daniel H. Efron Award, American College of Neuropsychopharmacology 1987-2002: Fellow, American Psychiatric Association 1987: Fellow, American College of Neuropsychopharmacology 1989: Donald and Lucy Dayton Professor, Mayo Foundation 1990: Distinguished Investigator, Mayo Foundation 1994: Listed in Best Doctors in America, 2nd Edition, published by Woodward/White, Inc., Aiken, SC 2000: Excellence in Teaching Recognition 1999-2000, Mayo Medical School 2002: Listed in Best Doctors in America, 2001-2002, published by Best Doctors, Inc., Aiken, SC

2002: “Highly Cited Researcher” in pharmacology (1981-1999), ISIHighlyCited.comSM

2003: Excellence in Teaching Recognition 2002-2003, Mayo Medical School

2003: Distinguished Fellow, American Psychiatric Association 2003-2013: Listed in Best Doctors in America®, 2003-2013, published by Best Doctors, Inc., Aiken, SC

2003: Excellence in Teaching Recognition 2003-2004, Mayo Clinic College of Medicine 2007: Distinguished Life Fellow, American Psychiatric Association 2010: The George N. Thompson Founder’s Award for Distinguished Service to the Society of Biological

Psychiatry. 2011: “Top Doctors” listing by U.S. News & World Report (in partnership with Castle Connolly Medical Ltd.)

Richelson-2

MEDICAL BOARD EXAMINATION: 1970: Diplomate of the National Board of Medical Examiners 1976: Certified in Psychiatry by the American Board of Psychiatry and Neurology MEDICAL LICENSURE: 1989 to present: Licensed to practice medicine in Florida SOCIETIES: American College of Neuropsychopharmacology (1978) American Psychiatric Association (1976) American Society for Clinical Pharmacology and Therapeutics (1988) American Society for Neurochemistry (1975) American Society for Pharmacology and Experimental Therapeutics (1975) Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) (1974) International Society for Affective Disorders (ISAD) (Fellow) (2008) Sigma Xi (1975) Society of Biological Psychiatry (1977) Society for Neuroscience (1974) SOCIETY OFFICES: Society of Biological Psychiatry, Assistant Secretary (1990-94) Society of Biological Psychiatry, Secretary/Treasurer (1994-98)

Society of Biological Psychiatry, Vice President (1998-99) Society of Biological Psychiatry, President (1999-2000) Society of Biological Psychiatry, Treasurer (2006-2018) EDITORIAL RESPONSIBILITY:

Member, Editorial Advisory Board, Progress in Neuro-Psychopharmacology, (Pergamon Press, Oxford) (1977-80) Member, Editorial Board, Mayo Clinic Proceedings (1980-82) Member, Editorial and Advisory Board, Molecular Pharmacology (1981-82) Associate Editor, The Journal of Clinical Psychiatry (1984-87) Member, Scientific Advisors, The Journal of Clinical Psychiatry (1987-93)

Member, Editorial Board, Geriatrics (1985-89) Member, Editorial Board, Journal of Neurochemistry (1986-93) Associate Editor, Psychopharmacology Bulletin (1988-99)

Member, Editorial Board, The Journal of Clinical Psychiatry (1993-2007) Member, Editorial Advisory Board, Biochemical Pharmacology (1996-2004) NATIONAL COMMITTEE MEMBERSHIP:

Biological Sciences Training Review Committee, National Institute of Mental Health (N.I.M.H.) (1977-83) Task Force on Drug Safety, American College of Neuropsychopharmacology (1984-85) Alcohol Biomedical Research Review Committee, National Institute on Alcohol Abuse and Alcoholism (1986-89)

Psychiatry Expert Committee, U.S. Pharmacopeia Council of Experts (2000-2005) Co-Chair, Credentials Committee, American College of Neuropsychopharmacology (2001-2002) Chair, Credentials Committee, American College of Neuropsychopharmacology (2002-2003) Member, NIH Study Section (ZRG1 BDCN-A) (2006-2011)

Member, Executive Council, Division of Neuropsychopharmacology, American Society for Pharmacology and Experimental Therapeutics (2008 -2010)

COMMITTEE CHAIRMANSHIPS:

Research Committee, Department of Psychiatry and Psychology, Mayo Foundation (1976-83) Biological Sciences Training Review Committee, N.I.M.H. (1980-83) A. E. Bennett Awards Committee, Society of Biological Psychiatry (1984-87)

A. E. Bennett Awards Committee, Society of Biological Psychiatry (1989-92)

Richelson-3

PUBLICATIONS: A. ORIGINAL RESEARCH 1. Allen, C.M., Jr., Richelson, E., and M.E. Jones: Studies on the Hydrolysis of Carbamyl Phosphate. In Current

Aspects of Biochemical Energetics, N.O. Kaplan and E.P. Kennedy (Eds.), Academic Press, New York, pp.401-412, 1966.

2. Richelson, E. and D. Nathans: Association of Bacteriophage Proteins and RNA in E. coli Infected with MS 2. Biochemical and Biophysical Research Communications 29:842-849, 1967.

3. Snyder, S.H. and Richelson, E.: Psychedelic Drugs: Steric Factors That Predict Psychotropic Activity. Proceedings of the National Academy of Sciences U.S.A. 60:206-213, 1968.

4. Amano, T., Richelson, E., and M. Nirenberg: Neurotransmitter Synthesis by Neuroblastoma Clones. Proceedings of the National Academy of Sciences U.S.A. 69:258-263, 1972.

5. Richelson, E. and E.J. Thompson: Transport of Neurotransmitter Precursors Into Cultured Cells. Nature New Biology 241:201-204,1973.

6. Richelson, E.: A Microwell Assay Method for the Biochemical Study of Cultured Cells. Analytical Biochemistry 52:563-573, 1973.

7. Richelson, E.: Stimulation of Tyrosine Hydroxylase Activity in an Adrenergic Clone of Mouse Neuroblastoma by Dibutyryl Cyclic AMP. Nature New Biology 242:175-177, 1973.

8. Richelson, E.: Regulation of Tyrosine Hydroxylase Activity in Mouse Neuroblastoma Clone N1E-115. Journal of Neurochemistry 21:1139-1145, 1973.

9. Richelson, E.: Studies on Transport of L-Tyrosine Into an Adrenergic Clone of Mouse Neuroblastoma. The Journal of Biological Chemistry 249:6218-6224, 1974.

10. Tuttle, J.B. and Richelson, E.: Ionic Excitation of a Clone of Mouse Neuroblastoma. Brain Research 84:129-135, 1975.

11. Richelson, E. and J.B. Tuttle: Diphenylhydantoin Inhibits Ionic Excitation of Mouse Neuroblastoma Cells. Brain Research 99:209-212, 1975.

12. Murphy, D.L., C.H. Donnelly , Richelson, E.: Substrate and Inhibitor-Related Characteristics of Monoamine Oxidase in C6 Rat Glial Cells. Journal of Neurochemistry 26:1231-1235, 1976.

13. Donnelly, C.H., Richelson, E. and D.L. Murphy: Properties of Monoamine Oxidase in Mouse Neuroblastoma N1E-115 Cells. Biochemical Pharmacology 25:1639-1643, 1976.

14. Honegger, P. and Richelson, E.: Biochemical Differentiation of Mechanically Dissociated Mammalian Brain in Aggregating Cell Culture. Brain Research 109:335-354, 1976.

15. Richelson, E.: Properties of Tyrosine Hydroxylation in Living Mouse Neuroblastoma Clone N1E-115. Journal of Neurochemistry 27:1113-1118, 1976.

16. Richelson, E.: Antipsychotics Block Muscarinic Acetylcholine Receptor-Mediated Cyclic GMP Formation in Cultured Mouse Neuroblastoma Cells. Nature 266:371-373, 1977.

17. Honegger, P. and Richelson, E.: Biochemical Differentiation of Aggregating Cell Cultures of Different Fetal Rat Brain Regions. Brain Research 133:329-339, 1977.

18. Richelson, E.: Lithium Ion Entry Through the Sodium Channel of Cultured Mouse Neuroblastoma Cells: A Biochemical Study. Science 196:1001-1002, 1977.

19. Richelson, E. and S. Divinetz-Romero: Blockade by Psychotropic Drugs of the Muscarinic Acetylcholine Receptor in Cultured Nerve Cells. Biological Psychiatry 12:771-785, 1977.

20. Honegger, P. and Richelson, E.: Kainic Acid Alters Neurochemical Development in Fetal Rat Brain Aggregating Cell Cultures. Brain Research 138:580-584, 1977.

21. Richelson, E.: Desensitization of Muscarinic Receptor-Mediated Cyclic GMP Formation by Cultured Nerve Cells. Nature 272:366-368, 1978.

22. Richelson, E.: Histamine H1 Receptor-Mediated Guanosine 3',5'-Monophosphate Formation by Cultured Mouse Neuroblastoma Cells. Science 201:69-71, 1978.

23. Richelson, E., F.G. Prendergast and S. Divinetz-Romero: Muscarinic Receptor-Mediated Cyclic GMP Formation by Cultured Nerve Cells: Ionic Dependence and Effects of Local Anesthetics. Biochemical Pharmacology 27:2039-2048, 1978.

24. Richelson, E.: Tricyclic Antidepressants Block Histamine H1 Receptors of Mouse Neuroblastoma Cells. Nature 274:176-177, 1978.

25. Murphy, D.L., C.H. Donnelly, Richelson, E. and R.W. Fuller: N-Substituted Cyclopropylamines as Inhibitors of MAO-A and -B Forms. Biochemical Pharmacology 27:1767-1769, 1978.

26. Trapp, B.D., P. Honegger, Richelson, E. and H. deF. Webster: Morphological Differentiation of Mechanically Dissociated Fetal Rat Brain in Aggregating Cell Cultures. Brain Res. 160:117-130, 1979.

27. Honegger, P. and Richelson, E.: Neurotransmitter Synthesis, Storage and Release by Aggregating Cell Cultures of Rat Brain. Brain Research 162:89-101, 1979.

28. Taylor, J.E. and Richelson, E.: Desensitization of Histamine H1 Receptor-Mediated Cyclic GMP Formation in Mouse Neuroblastoma Cells. Molecular Pharmacology 15:462-471, 1979.

29. Gorkin, R.A. and Richelson, E.: Lithium Ion Accumulation by Cultured Glioma Cells. Brain Research 171:365-368, 1979.

Richelson-4

30. Fredrickson, P.A. and Richelson, E.: Hallucinogens Antagonize Histamine H1 Receptors of Cultured Mouse Neuroblastoma Cells. European Journal of Pharmacology 56:261-264, 1979.

31. Tuttle, J.B. and Richelson, E.: Phenytoin Action on the Excitable Membrane of Mouse Neuroblastoma. Journal of Pharmacology and Experimental Therapeutics 211:632-637, 1979.

32. Figge, J., P. Leonard, Richelson, E.: Tricyclic Antidepressants: Potent Blockade of Histamine H1 Receptors of Guinea Pig Ileum. Eur. Journal of Pharmacology 58:479-483, 1979.

33. Taylor, J.E., E. El-Fakahany, Richelson, E.: Long-Term Regulation of Muscarinic Acetylcholine Receptors on Cultured Nerve Cells. Life Sciences 25:2181-2187, 1979.

34. El-Fakahany, E. and Richelson, E.: Temperature-Dependence of Muscarinic Acetylcholine Receptor Activation, Desensitization and Resensitization. Journal of Neurochemistry, 34:1288-1295, 1980.

35. Knodel, E.L. and Richelson, E.: Methionine-Enkephalin Immunoreactivity in Fetal Rat Brain Cells in Aggregating Culture and in Mouse Neuroblastoma Cells. Brain Research 197:565-570,1980.

36. El-Fakahany, E. and Richelson, E.: Regulation of Muscarinic Receptor-Mediated Cyclic GMP Synthesis by Cultured Mouse Neuroblastoma Cells. J. Neurochemistry, 35:941-948, 1980.

37. Taylor, J.E. and Richelson, E.: High-Affinity Binding of Tricyclic Antidepressants to Histamine H1 Receptors: Fact and Artifact. Eur. J. Pharmacology, 67:41-46, 1980.

38. El-Fakahany, E. and Richelson, E.: Involvement of Calcium Channels in Short-Term Desensitization of Muscarinic Receptor-Mediated Cyclic GMP Formation in Mouse Neuroblastoma Cells. Proceedings National Academy of Sciences, 77:6897-6901, 1980.

39. Wastek, G.J., J.R. Lopez, Richelson, E.: Demonstration of a Muscarinic Receptor-Mediated Cyclic GMP-Dependent Hyperpolarization of the Membrane Potential of Mouse Neuroblastoma Cells Using [3H]Tetraphenylphosphonium. Mol. Pharmacology, 19:15-20, 1981.

40. El-Fakahany, E. and Richelson, E.: Effects of Lanthanides on Muscarinic Acetylcholine Receptor Function. Molecular Pharmacology, 19:282-290, 1981.

41. Gorkin, R.A. and Richelson, E.: Lithium Transport by Mouse Neuroblastoma Cells. Neuropharmacology, 20:791-801, 1981.

42. El-Fakahany, E. and Richelson, E.: Phenoxybenzamine and Dibenamine Interactions With Calcium Channel Effectors of the Muscarinic Receptor. Mol. Pharmacology, 20:519-525, 1981.

43. Gilbert, J.A., E.L. Knodel, S.D. Stenstrom, Richelson, E.: Function and Regulation of Met5-Enkephalin and Its Receptors in Murine Neuroblastoma Cells. Journal of Biological Chemistry 257:1274-1281, 1982.

44. Petersen, R.C. and Richelson, E.: Anticholinergic Activity of Imipramine and Some Analogs at Muscarinic Receptors of Cultured Mouse Neuroblastoma Cells. Psychopharmacology, 76:26-28, 1982.

45. Taylor, J.E. and Richelson, E.: High Affinity Binding of [3H]Doxepin to Histamine H1 Receptors in Brain. European Journal of Pharmacology, 78:279-285, 1982.

46. Carlson, J., A. Smith, Richelson, E.: Lack of Function of Histamine H1 and Muscarinic Acetylcholine Receptors of Mouse Neuroblastoma Cells Growth in Serum-Free Medium. In Vitro, 18:175-178, 1982.

47. Stenstrom, S. and Richelson, E.: Acute Effect of Ethanol on Prostaglandin E1-Mediated Cyclic AMP Formation by a Murine Neuroblastoma Clone. Journal of Pharmacology and Experimental Therapeutics 221:334-341, 1982.

48. Taylor, J.E., T.L. Yaksh, Richelson, E.: Agonist Regulation of Muscarinic Acetylcholine Receptors in Rat Spinal Cord. Journal of Neurochemistry, 39:521-524, 1982.

49. Taylor, J.E., T.L. Yaksh, Richelson, E.: Histamine H1 Receptors in the Brain and Spinal Cord of the Cat. Brain Research 243:391-394, 1982.

50. Thompson, D.G., Richelson, E. and J.-R. Malagelada: Perturbation of Gastric Emptying and Duodenal Motility Through the Central Nervous System. Gastroenterology, 83:1200-1206, 1982.

51. El-Fakahany, E. and Richelson, E.: Antagonism by Antidepressants of Muscarinic Acetylcholine Receptors of Human Brain. British Journal of Pharmacology, 78:97-102, 1983.

52. Thompson, D.G., Richelson, E. , and J.-R. Malagelada: Perturbation of Upper Gastrointestinal function by Cold Stress. Gut, 24:277-283, 1983.

53. El-Fakahany, E. and Richelson, E.: Effect of some calcium antagonists on muscarinic receptor-mediated cyclic GMP formation. Journal of Neurochemistry, 40:(3):705-710, 1983.

54. El-Fakahany, E., J.R. Lopez,, Richelson, E.: Lanthanum binding to murine neuroblastoma cells. Journal of Neurochemistry, 40:1687-1691, 1983.

55. Snider, R.M. and Richelson, E.: Thrombin stimulates cyclic GMP formation in murine neuroblastoma cells (clone N1E-115). Science 221:566-568, 1983.

56. McKinney, M., R.M. Snider, Richelson, E.: Thrombin Binding to Human Brain and Spinal Cord. Mayo Clinic Proceedings, 58:829-831, 1983.

57. Kanba, S. and Richelson, E.: Antidepressants are weak competitive antagonists of histamine H2 receptors in dissociated tissue from the guinea pig hippocampus. European Journal of Pharmacology, 94:313-318, 1983.

58. Richelson, E. and M. Johnson: Sodium-dependent lithium ion efflux from murine neuroblastoma and rat glioma cells is a minor pathway for efflux of lithium ions. Psychopharmacology, 82:27-29, 1984.

59. Snider, R.M. and Richelson, E.: Bradykinin receptor-mediated cyclic GMP formation in a nerve cell population (murine neuroblastoma clone N1E-115). Journal of Neurochemistry. 43:1749-1754, 1984.

Richelson-5

60. El-Fakahany, E., M. Pfenning, Richelson, E.: Kinetic effects of terbium ions on muscarinic acetylcholine receptors of murine neuroblastoma cells. Journal of Neurochemistry, 42:863-869, 1984.

61. Snider, R.M., M. McKinney, C. Forray, Richelson, E.: Neurotransmitter receptors mediate cyclic GMP formation by involvement of phospholipase A2 and arachidonic acid metabolites. Proceedings of the National Academy of Sciences, U.S.A., 81:3905-3909, 1984.

62. Kanba, S. and Richelson, E.: Histamine H1 receptors in human brain labeled with [3H]doxepin. Brain Research 304:1-7, 1984.

63. McKinney, M., S. Stenstrom, Richelson, E.: Muscarinic responses and binding in a murine neuroblastoma clone (N1E-115): Selective loss with subculturing of the low-affinity agonist site mediating cyclic GMP formation. Molecular Pharmacology, 26:156-163, 1984.

64. Gilbert, J.A. and Richelson, E.: Neurotensin stimulates formation of cyclic GMP in murine neuroblastoma clone N1E-115. European Journal of Pharmacology, 99:245-246, 1984.

65. Richelson, E. and A. Nelson: Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. European Journal of Pharmacology 103:197-204, 1984.

66. Richelson, E. and A. Nelson: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Exp. Ther. 230:94-102, 1984.

67. Snider, R.M., M. McKinney, J.W. Fenton, II, Richelson, E.: Activation of cyclic nucleotide formation in murine neuroblastoma N1E-115 cells by modified human thrombin. Journal of Biological Chemistry 259:9078-9081, 1984.

68. Gilbert, J.A., M.A. Pfenning, Richelson, E.: Angiotensin I, II, and III stimulate formation of cyclic GMP in murine neuroblastoma clone N1E-115. Biochemical Pharmacology 33:2527-2530, 1984.

69. Richelson, E. and M. Pfenning: Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. European Journal of Pharmacology 104:277-286, 1984.

70. Turner, S.T., M. Johnson, E. Boerwinkle, Richelson, E., C.F. Sing: Distribution of sodium-lithium countertransport and its relationship to blood pressure in a large sample of blood donors. Hypertension, 7:955-962, 1985.

71. Gilbert, J.A. and Richelson, E.: Influence of delta opioid receptors on production of labeled-methionine5-enkephalin in murine neuroblastoma cells. J. Neurochemistry 44:922-928, 1985.

72. McKinney, M., S. Stenstrom, Richelson, E.: Multiple muscarinic cholinergic receptors in cultured murine neuroblastoma cells (clone N1E-115): mediation of separate responses by high-affinity and low-affinity agonist-receptor conformations. Molecular Pharmacology, 27:223-235, 1985.

73. Stenstrom, S., M. Seppala, M. Pfenning, Richelson, E.: Inhibition by ethanol of forskolin-stimulated adenylate cyclase in a murine neuroblastoma clone (N1E-115). Biochemical Pharmacology, 34:3655-3659, 1985.

74. Forray, C. and Richelson, E.: Glucocorticoids potentiate the prostaglandin E1-mediated cyclic amp formation by a cultured murine neuroblastoma clone. Journal of Neurochemistry 45:79-85, 1985.

75. Kanba, S., M. Pfenning, Richelson, E.: Lithium ions inhibit function of low- but not high-affinity muscarinic receptors of murine neuroblastoma cells (clone N1E-115). Psychopharmacology, 86:413-416, 1985.

76. Richelson, E., K. Snyder, J. Carlson, M. Johnson, S. Turner, A. Lumry, E. Boerwinkle and C.F. Sing: Lithium ion transport by erythrocytes of randomly selected blood donors and manic-depressive patients: lack of association with affective illness. American Journal of Psychiatry 143:457-462, 1986.

77. Gilbert, J.A., J. Moses, M.A. Pfenning, Richelson, E.: Neurotensin and its analogs - correlation of specific binding with stimulation of cyclic GMP formation in neuroblastoma clone N1E-115. Biochemical Pharmacology, 35:391-397, 1986.

78. Lin, S.C., K. Olson, H. Okazaki, Richelson, E.: Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine. Journal of Neurochemistry, 46:274-290, 1986.

79. Stenstrom, S. and Richelson, E.: Acute effect of ethanol on the guanylate cyclase system of murine neuroblastoma cells (clone N1E-115). Journal of Pharmacology and Experimental Therapeutics 236:458-463, 1986.

80. Kanba, K.S., S. Kanba, H. Okazaki, Richelson, E.: Binding of [3H]Neurotensin in human brain: Properties and distribution. Journal of Neurochemistry, 46:946-952, 1986.

81. McKinney, M., M. Pfenning, Richelson, E.: The effect of the antitumor drug caracemide on the neurochemistry of murine neuroblastoma cells (clone N1E-115). Biochemical Pharmacology, 35:2615-2622, 1986.

82. Lin, S.-C. and Richelson, E.: Human skin fibroblasts have low levels of muscarinic binding sites with no function: Report of findings on cells from five affectively-ill patients and two controls. American Journal of Psychiatry 143:658-660, 1986.

83. Snider, R.M., C. Forray, M. Pfenning, Richelson, E.: Neurotensin stimulates inositol phospholipid metabolism and calcium mobilization in murine neuroblastoma clone N1E-115. Journal of Neurochemistry 47:1214-1218, 1986.

84. McKinney, M. and Richelson, E.: Blockade of N1E-115 murine neuroblastoma muscarinic receptor function by agents that affect the metabolism of arachidonic acid. Biochemical Pharmacology 35:2389-2397, 1986.

Richelson-6

85. Snider, R.M., M. McKinney, Richelson, E.: Thrombin binding and stimulation of cyclic guanosine monophosphate formation in neuroblastoma cells. Seminars in Thrombosis and Hemostasis 12:253-262, 1986.

86. Kanba, S., M. Pfenning, K.S. Kanba, Richelson, E.: Lithium ions have a potent and selective inhibitory effect on cyclic GMP formation stimulated by neurotensin, angiotensin II, and bradykinin. European Journal of Pharmacology 126:111-116, 1986.

87. McKinney, M. and Richelson, E.: Muscarinic responses and binding in a murine neuroblastoma clone (N1E-115): Carbachol mediates cyclic GMP formation by binding to a low-affinity subtype and cyclic AMP reduction by binding to a high-affinity subtype. Molecular Pharmacology 30:207-211, 1986.

88. Boerwinkle, E., S.T. Turner, R. Weinshilboum, M. Johnson, Richelson, E., C.F. Sing: Analysis of the distribution of erythrocyte sodium lithium countertransport in a sample representative of the general population. Genetic Epidemiology 3:365-378, 1986.

89. Kanba, S., K.S. Kanba, Richelson, E.: The protein kinase C activator, 12-0-tetradecanoylphorbol-13-acetate (TPA), inhibits muscarinic (M1) receptor-mediated inositol phosphate release and cyclic GMP formation in murine neuroblastoma cells (clone N1E-115). European Journal of Pharmacology 125:155-156, 1986.

90. Richelson, E., S. Stenstrom, C. Forray, L. Enloe and M. Pfenning: Effects of chronic exposure to ethanol on the prostaglandin E1 receptor-mediated response and binding in a murine neuroblastoma clone (N1E-115). Journal of Pharmacology and Experimental Therapeutics 239:687-692, 1986.

91. Wander, T.J., A. Nelson, H. Okazaki, Richelson, E.: Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur. J. Pharmacology 132:115-121, 1986.

92. Gilbert, J.A. and Richelson, E.: LANT-6, xenopsin, and neuromedin N stimulate cyclic GMP at neurotensin receptors. European Journal of Pharmacology 129:379-383, 1986.

93. Turner, S.T., E. Boerwinkle, M. Johnson, Richelson, E., C.F. Sing: Sodium-lithium countertransport in erythrocytes of ambulatory hypertensive and normotensive patients. Hypertension 9:24-34,1987.

94. Kanba, K.S. and Richelson, E.: Comparison of the stimulation of inositol phospholipid hydrolysis and of cyclic GMP formation by neurotensin, some of its analogs and neuromedin N in neuroblastoma clone N1E-115. Biochemical Pharmacology, 36:869-874, 1987.

95. Wander, T.J., A. Nelson, H. Okazaki, Richelson, E.: Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. European Journal of Pharmacology 143:279-282, 1987.

96. Gilbert, J.A., P. D. Hanson, D.J. McCormick, Richelson, E.: Rapid degradation of neurotensin by intact murine neuroblastoma cells (clone N1E-115). Journal of Neurochemistry 49:1845-1852, 1987.

97. Kanba, K.S., S. Kanba, A. Nelson, H. Okazaki, Richelson, E.: [3H]Neurotensin(8-13) binds in human brain to the same sites as does [3H]neurotensin but with higher affinity. Journal of Neurochemistry 50:131-137, 1988.

98. Gilbert, J.A., T.R. Strobel, Richelson, E.: Desensitization of neurotensin receptor-mediated cyclic GMP formation in neuroblastoma clone N1E-115. Biochem. Pharmacol. 37:2833-2838, 1988.

99. Oakes, S.G., P.A. Iaizzo, Richelson, E., G. Powis: Histamine-induced intracellular free Ca2+, inositol phosphates and electrical changes in murine N1E-115 neuroblastoma cells. J. Pharmacol. Exp. Ther. 247:114-121, 1988.

100. El-Fakahany, E.E., W. Surichamorn, C.L. Amrhein, S. Stenstrom, C.L. Cioffi, Richelson, E., M. McKinney. Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepine. J. Pharmacol. Exp. Ther. 247:934-940, 1988.

101. Gilbert, J.A., D.J. McCormick, M.A. Pfenning, K.S. Kanba, L.J. Enloe, A. Moore, Richelson, E.: Neurotensin[8-13]: comparison of novel analogs for stimulation of cyclic GMP formation in neuroblastoma clone N1E-115 and receptor binding to human brain and intact N1E-115 cells. Biochem. Pharmacol. 38:3377-3382, 1989.

102. Donato Di Paola, E. and Richelson, E.: Cardiovascular effects of neurotensin and some analogues on rats. European Journal of Pharmacology 175:279-283, 1990.

103. McKinney, M., C. Bolden, C. Smith, A. Johnson, Richelson, E.: Selective blockade of receptor-mediated cyclic GMP formation in N1E-115 neuroblastoma cells by an inhibitor of nitric oxide synthesis. Eur. J. Pharmacol. 178:139-140, 1990.

104. Kanba, S., K.S. Kanba, M. McKinney, M. Pfenning, R. Abraham, S. Nomura, L. Enloe and Richelson, E.: Desensitization of muscarinic M1 receptors of murine neuroblastoma cells (clone N1E-115) without receptor down-regulation and protein kinase C activity. Biochemical Pharmacology 40:1005-1014, 1990.

105. Bolden, C., B. Cusack, Richelson, E.: Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells. European J. Pharmacol. 192:205-206, 1991.

106. Kanba, S., G. Yagi, E. Oguchi, T. Nakaki, R. Kato, Richelson, E.: Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain. Japanese J. Psychiatry Neurol. 45:133-134, 1991.

107. Larson, E.W., M.A. Pfenning, Richelson, E.: Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart. Psychopharmacology 103:162-165, 1991.

108. Richelson, E., A. Nelson, R. Neeper: The binding of benzodiazepines and some major metabolites at their sites in normal human frontal cortex in vitro. J. Pharmacol. Exp. Ther. 256:897-901, 1991.

Richelson-7

109. Neeper, R., Richelson, E., A. Nelson: Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain. Neuropharmacology 30:527-529, 1991.

110. Cusack, B., Stanton, T., Richelson, E.: Developmental regulation of neurotensin receptor expression and function in murine neuroblastoma clone N1E-115. European J. Pharmacology 206:339-342, 1991.

111. Kanba, S., G. Yagi, T. Nakaki, R. Kato, Richelson, E.: Potentiation by a sodium channel activator of effects of lithium ion on cyclic AMP, cyclic GMP and inositol phosphates. Neuropharmacology 30:497-500, 1991.

112. Ahlskog, J.E., Richelson, E., A. Nelson, P.J. Kelly, H. Okazaki, G.M. Tyce, J.A. van Heerden, S.L. Stoddard, S.W. Carmichael: Reduced caudate D2-dopamine and muscarinic-cholinergic receptor densities in living fluctuating Parkinson patients. Annals of Neurology 30:185-191, 1991.

113. Al-Rodhan, N.R.F., Richelson, E., J.A. Gilbert, D.J. McCormick, K.S. Kanba, M.A. Pfenning, A. Nelson, E.W. Larson, T.L. Yaksh: Structure - antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem. Brain Research, 557:227-235, 1991.

114. Kanba, S., N. Sasakawa, T. Nakaki, K.S. Kanba, G. Yagi, R. Kato, Richelson, E.: Two possibly distinct prostaglandin-E1 receptors in N1E-115 clone - one mediating inositol trisphosphate formation, cyclic GMP formation, and intracellular calcium mobilization and the other mediating cyclic amp formation. Journal of Neurochemistry 57:2011-2015, 1991.

115. Bolden, C., B. Cusack, Richelson, E.: Antagonism by antimuscarinic and neuroleptics compounds at the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells. J. Pharmacol. Exp. Ther. 260:576-580, 1992.

116. Watson, M.A., Yamada, M., Yamada, Mi., Cusack, B., Veverka, K., Bolden-Watson, C., Richelson, E.: The rat neurotensin receptor expressed in Chinese Hamster Ovary cells mediates the release of inositol phosphates. J. Neurochem. 59:1967-1970, 1992.

117. Yamada, M., Yamada, Mi. and Richelson, E.: Block of neurotensin receptor down-regulation by an aminosteroid in N1E-115 cells. Eur. J. Pharmacol. - Mol. Pharmacol. Sect. 226:187-188, 1992.

118. Yamada, Mi., Yamada, M., Watson, M.A., Richelson, E.: Neurotensin stimulates cyclic AMP formation in CHO-rNTR-10 expressing the rat neurotensin receptor. Eur. J. Pharmacol. - Mol. Pharmacol. Sect. 244:99-101, 1993.

119. Donato Di Paola, E., Cusack, B., Yamada, M., Richelson, E.: [D-lys8]NT(8-13) induced down-regulation of neurotensin receptors in neuroblastoma murine clone N1E-115. J. Pharmacol. Exp. Ther.264:1-5, 1993.

120. Cusack, B. and Richelson, E.: A method for radioligand binding assays using a robotic workstation. J. Receptor Res., 13:123-134, 1993.

121. Bolden-Watson C. and Richelson, E.: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences 52:1023-1029, 1993.

122. Yamada, M., Yamada, Mi. and Richelson, E.: Further characterization of neurotensin receptor desensitization and down-regulation in N1E-115 neuroblastoma cells. Biochem. Pharmacol. 45: 2149-2154,1993.

123. Stanton, T.T., Bolden-Watson, C., Cusack, B., Richelson, E.: Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem. Pharmacol. 45: 2352-2354, 1993.

124. Bolden-Watson, C., Watson, M.A., Murray, K.D., Isackson, P.J., Richelson, E.: Haloperidol but not clozapine increases neurotensin receptor messenger RNA levels in rat substantia nigra. J. Neurochem. 61:1141-1143, 1993.

125. Watson, M., Isackson, P., Makker, M., Yamada, M., Yamada, Mi., Cusack, B., Richelson, E.: Identification of a polymorphism in the human neurotensin receptor gene. Mayo Clinic Proceedings 68:1043-1048, 1993.

126. Yamada, M., Yamada, Mi., Richelson, E.: Role of signal transduction systems in neurotensin receptor down-regulation induced by agonist in murine neuroblastoma clone N1E-115 cells. J. Pharmacol. Exp. Ther. 267:128-133, 1993.

127. Cusack, B., Richelson, E., Pang, Y.-P., Zaidi, J., A.P. Kozikowski: Pharmacological studies on novel neurotensin mimetics: discovery of a pharmacologically unique agent exhibiting concentration dependent dual effects as antagonist and agonist. Molecular Pharmacology 44:1036-1040, 1993.

128. Kohl, R.L., Sandoz, G.R., Reschke, M.F.,Calkins, D.S., Richelson, E.: Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine. J. Clin. Pharmacology 33:1092-1103, 1993

129. Cusack, B., Nelson, A., Richelson, E.: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology, 114:559-565, 1994.

130. Dodd, D.S., Kozikowski, A.P., Cusack, B., Richelson, E.: Synthesis of partially non-peptidic neurotensin mimetics. Bioorganic & Medicinal Chemistry Letters 4:1241-1246, 1994.

131. Pang, Y.-P., Zaidi, J., Kozikowski, A.P., Cusack, B., Richelson, E.: Rational design of novel neurotensin mimetics: discovery of a pharmacologically unprecedented agent exhibiting concentration-dependent dual effects as antagonist and full agonist. Journal of Computer-Aided Molecular Design 8:433-440, 1994.

132. Yamada, Mi.,Yamada, M., Watson, M.A., Richelson, E.: Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes the PI hydrolysis but not cyclic AMP formation in CHO-K1 cells. Molecular Pharmacology 46:470-476, 1994.

Richelson-8

133. Shintani, F., Kanba, S., Nakaki, T., Nakamura, R., Sato, K.,Yagi, G., Richelson, E., Kato, R., M. Asai: Inhibition by lithium of cyclic GMP formation without inhibition of nitric oxide generation in the mouse neuroblastoma cell (N1E-115). Neuropsychopharmacology 11:119-124,1994.

134. Kanba, S., Suzuki, E., Nomura, S., Nakaki, T., Yagi, G., Asai, M., Richelson, E.: Affinity of neuroleptics for D1 receptor of human brain striatum. Journal of Psychiatry & Neuroscience. 19:265-9, 1994.

135. Yamada, M., Yamada, Mi. and Richelson, E.: Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain. Neuroscience 64:405-417, 1995.

136. Yamada, M., Cho, T., Coleman, N.J., Yamada, Mi., Richelson, E.: Regulation of daily rhythm of body temperature by neurotensin receptor in rats. Research Communications in Molecular Pathology and Pharmacology 87:323-332, 1995.

137. Mach, J.R., Jr., Dysken, M.W., Richards, H., Kuskowksi, M., Richelson, E., Holden, L., Jilk, K.M.: Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary study. J. Am. Geriatric Society 43:491-495, 1995.

138. Cusack, B., McCormick, D.J., Pang, Y.-P., Souder, T., Garcia, R., Richelson, E.: Pharmacological and biochemical profiles of unique neurotensin(8-13) analogs exhibiting species selectivity, stereo-selectivity and super-agonism. Journal of Biological Chemistry 270:18359-18366, 1995.

139. Kozikowski, A.P., Dodd, D.S., Zaidi, J., Pang, Y.-P., Cusack, B., Richelson, E.: Synthesis of partial nonpeptidic mimetics as potential neurotensin agonists and antagonists. J. Chem. Soc. - Perkin Trans. 1:1615-1621, 1995.

140. Yamada, M., Bolden-Watson, C., Watson, M.A., Cho, T., Coleman, N.J., Yamada, Mi., Richelson, E.: Regulation of neurotensin receptor mRNA expression by the receptor antagonist SR 48692 in the rat midbrain dopaminergic neurons. Molecular Brain Research 33:343-346, 1995.

141. Yamada, Mi., Ohata, H., Momose, K., Yamada, M., Richelson, E.: Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2. Research Communications in Molecular Pathology and Pharmacology 90:37-47, 1995.

142. Yamada, Mi., Momose, K., Richelson, E., M. Yamada: Sodium nitroprusside induced apoptotic cellular death via production of hydrogen peroxide in murine neuroblastoma N1E-115 cells. Journal of Pharmacology and Toxicological Methods 35:11-17, 1996.

143. Cusack, B., Groshan, K., McCormick, D.J., Pang, Y.P., Perry, P., Phung, C.-T., Souder, T. and E. Richelson: Chimeric rat/human neurotensin receptors localize a region of the receptor sensitive to binding of a novel, species specific, picomolar affinity peptide. Journal of Biological Chemistry 271:15054-15059,1996.

144. Pang, Y.-P., Cusack, B., Groshan, K., Richelson, E.: Proposed ligand binding site of the transmembrane receptor for neurotensin(8-13). Journal of Biological Chemistry 271:15060-15068, 1996.

145. Roemer, R., Richelson, E., Shagass, C., Leventhal, L: A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs. J. Psychiatry Neurosci. 21(5):1-9, 1996.

146. Yamada, M., Groshan, K., Phung, C.-T., Yamada, Mi., Hisamitsu, T., Richelson, E.: The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson’s disease brain. Molecular Brain Research 44:12-20, 1997.

147. Le, F., Groshan, K., Zeng, X.P., Richelson, E.: Characterization of the genomic structure, promoter region, and a tetranucleotide repeat polymorphism of the human neurotensin receptor gene. Journal of Biological Chemistry 272:1315-1322, 1997.

148. Le, F., X. P. Zeng, Richelson, E.: Tetranucleotide repeat polymorphism in the human neurotensin receptor (NT-R) gene (CG 96071801). Clinical Genetics 51:76-77, 1997.

149. Zeng, X.P., Le, F., Richelson, E.: Muscarinic m4 receptor activation by some atypical antipsychotic drugs. European Journal of Pharmacology 321:349-354, 1997.

150. Hong, F., Pang, Y.-P., Cusack, B., Richelson, E.: Design, synthesis and pharmacological test of a quinoline based, nonpeptidic analog of neurotensin(8-13). Journal of the Chemical Society. Perkin Transactions 1 14: 2083-2088, 1997.

151. Tatsumi, M., Groshan, K., Blakely, R.D., Richelson, E.: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology 340:249-258, 1997.

152. Hong, F., Zaidi, J., Pang, Y.-P., Cusack, B., Richelson, E.: Design, synthesis, and pharmacological evaluation of active pyrrole based nonpeptide analogues of neurotensin(8-13). J. Chem. Soc. - Perkin Trans. 1. 20:2997-3003, 1997.

153. Tyler, B.M., McCormick, D.J., Hoshall, C.V., Douglas, C.L., Groshan, K., Lacy, B.W., Cusack, B., Richelson, E.: Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Letters 421:280-284, 1998.

154. Carlier, P.R., Lo, M. M-C., Lo, P. C-K., Richelson, E., Tatsumi, M., Reynolds, I.J., Sharma, T.A. Characterization of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-specific dopamine-reuptake inhibitor based on the on the gamma-amino alcohol functional group. Bioorganic & Medicinal Chemistry Letters 8: 487-492, 1998.

Richelson-9

155. Tyler, B.M., Groshan, K., Cusack, B. and Richelson, E.: In vivo studies with low doses of levocabastine and diphenhydramine, but not pyrilamine antagonize neurotensin-mediated antinociception. Brain Research 787:78-84, 1998.

155. Tyler, B.M., Cusack, B. Douglas, C.L., Souder, T. and Richelson, E.: Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Research 792:246-252, 1998.

156. Fauq, A.H., Ziani-Cherif, C., Richelson, E.: Synthesis of (S)- and (R)-enantiomers of p-(4-hydroxybenzoyl)phenylalanine, useful photoaffinity labeling probes for peptide-protein binding sites, Tetrahedron: Asymmetry 9 (13):2333-2338, 1998.

157. Fauq, A.H., Hong, F., Cusack, B., Tyler, B.M., Pang, Y.-P., Richelson, E.: Synthesis of (2S)-2-amino-3-(1H-4-indolyl)propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides. Tetrahedron: Asymmetry 9 (23): 4127-4134, 1998.

158. Tatsumi, M., Jansen, K., Blakely, R.D., Richelson, E.: Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol. 368: 277-283, 1999.

159. Craig, A.G., Norberg, T., Griffin, D., Hoeger, C., Akhtar, M., Schmidt, K., Low, W., Dykert, J., Richelson, E., Navarro, V., Mazella, J., Watkins, M., Hillyard, D., Imperial, J., Cruz, L.J., Olivera, B.M.: Contulakin-G, an O-glycosylated invertebrate neurotensin. J. Biol. Chem. 274:13752-9, 1999.

160. Tyler, B.M., McCormick, D.J., Jansen, K., Douglas, C.L., Boules, M., Stables, J.A., Cusack, B., Zhao, L., Lacy, B., Fauq, A., Richelson, E.: Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression Proc. Natl. Acad. Sci. U.S.A. 96:7053-7058, 1999.

161. Tyler, B.M., Douglas, C.L., Fauq, A., Pang, Y.-P., Stables, J.A., Cusack, B., McCormick, D.J., Richelson, E.: In vitro binding and CNS effects of novel neurotensin agonists that cross the blood brain barrier. Neuropharmacology 38:1027-1034, 1999.

162. Jansen, K. and Richelson, E.: Detection of peptide nucleic acids in tissue extracts of treated animals by gel mobility shift assay. Journal of Biochemical and Biophysical Methods, 42:31-34, 2000.

163. Cusack, B., Chou, T., Jansen, K., McCormick, D.J., Richelson, E.: Analysis of binding sites and efficacy of a species specific peptide at rat and human neurotensin receptors. J. Peptide Research 55:72-80, 2000.

164. Cusack, B., Boules, M., Tyler, B.M., Fauq, A., McCormick, D.J., Richelson, E.: Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Research 856: 48-54, 2000.

165. Tyler-McMahon, B.M., Stewart, J.A., Farinas, F., McCormick, D.J., Richelson, E.: A highly potent neurotensin analog that causes hypothermia and antinociception. European Journal of Pharmacology 390:107-111, 2000.

166. Boules, M., Cusack, B., Zhao, L., Fauq, A.; McCormick, D.J., Richelson, E.: A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Research 865:35-44, 2000.

167. Cusack, B., Jansen, K., McCormick, D.J., Chou, T., Pang, Y.-P., Richelson, E.: A single amino acid of the human and rat neurotensin receptors (subtype 1) determines the pharmacological profile of a species selective neurotensin agonist. Biochemical Pharmacology 60:793-801, 2000.

168. Richelson, E. and T. Souder: Binding of neuroleptics to human brain receptors: focus on newer generation compounds. Life Sciences 68:29-39, 2000.

169. McMahon, B.M., Stewart, J.A., Jackson, J., Fauq, A., McCormick, D.J., Richelson, E.: Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain. Brain Research 904:345-349, 2001.

170. Boules, M., Warrington, L, Fauq, A., McCormick, D., Richelson, E. A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity. European Journal of Pharmacology 426:73-76, 2001.

171. Tyler-McMahon, B.M., Stewart, J.A., Jackson, J., Bitner, M.D., Fauq, A., McCormick, D.J., Richelson, E.: Altering behavioral responses and dopamine transporter protein with antisense peptide nucleic acids. Biochemical Pharmacology, 62:929-932, 2001.

172. Boules, M.,Warrington, L, Fauq, A., McCormick, D., Richelson, E. Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. European Journal of Pharmacology 428:227-233, 2001.

173. Katz, L.M., Wang, Y., McMahon, B., Richelson, E.: Neurotensin analog NT69L induces rapid and prolonged hypothermia after hypoxic-ischemia. Academic Emergency Medicine 8:1115-1121, 2001.

174. Boules, M., McMahon, B.M., Warrington, L., Stewart, J., Jackson, J., Fauq, A., McCormick, D., Richelson, E. A neurotensin analog selective for hypothermia over antinociception, and exhibiting atypical neuroleptic-like properties. Brain Research 919:1-11, 2001.

175. McMahon, B.M., Stewart, J.A., Jackson, J., Bitner, M., Fauq, A., McCormick, D.J., and Richelson, E.: Peptide nucleic acids specifically cause antigene effects in vivo by systemic injection. Life Sciences 71:325-337, 2002.

176. McMahon, B.M., Mays, D., Lipsky, J., Stewart, J.A., Fauq, A., Richelson, E.: Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense and Nucleic Acid Drug Development 12:65-70, 2002.

Richelson-10

177. McMahon, B.M., Stewart, J.A., Fauq, A., Younkin, S., Younkin, L., Richelson, E.: Using peptide nucleic acids as gene-expression modifiers to reduce β- amyloid levels. Journal of Molecular Neuroscience 19:71-76, 2002.

178. Hong, F., Zaidi, J., Cusack, B., Richelson, E.: Synthesis and biological studies of novel potent neurotensin(8-13) mimetics. Bioorganic & Medicinal Chemistry 10:3849-3858, 2002.

179. Fredrickson, P., Boules, M., Yerbury, S., and Richelson, E.:Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats. European Journal of Pharmacology 458:111-118, 2003.

180. Shilling, P.D., Richelson, E., and Feifel, D.:The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behavioural Brain Research 143:7-14, 2003.

181. Fredrickson, P., Boules, M., Yerbury, S., and Richelson, E.: Novel neurotensin analog blocks the initiation and expression of nicotine-induced locomotor sensitization. Brain Research 458:111-118, 2003.

182. Boules, M.., McMahon, B., Wang, R., Warrington, L., Stewart, J., Yerbury, S., Fauq, A., McCormick, D., Richelson, E.: Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood brain barrier. Brain Research 979:245-248, 2003.

183. Gordon, C.J., McMahon, B., Richelson, E., Padnos, B., and Katz, L.: Neurotensin analog NT77 induces regulated hypothermia in the rat. Life Sciences 73:2611-23, 2003.

184. Shilling, P.D., Melendez, G., Priebe, K., Richelson, E., Feifel, D.Neurotensin agonists block the prepulse inhibition deficits produced by a 5HT2A and an α1 agonist. Psychopharmacology (Berl) 175:353-359, 2004.

185. Boules, M., Williams, K., Gollatz, E., Fauq, A., and Richelson, E: Down-regulation of amyloid precursor protein by peptide nucleic acid in vivo. Journal of Molecular Neuroscience 24 (1):123-128 2004.

186. Wang, R., Boules, M.,Tiner, W., and Richelson, E.: Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro. Brain Research 1025 (1-2): 21-28, 2004.

187. Fantegrossi, W., Ko, M.C.H., Woods, J.H., Richelson, E.: Antinociceptive, hypothermic, hypotensive and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacology, Biochemistry and Behavior 80:341-349, 2005.

188. Wang R, Boules M, Gollatz E, Williams K, Tiner W, Richelson E.: Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain. Molecular Brain Research 138:24-34, 2005.

189. Zaidi JH, Naeem F, Ambreen N, Khan KM, Pang YP, Cusack B, Richelson E, Anwar A, Voelter W. Pyrrole-based partial peptidic mimic of neurotensin (8-13): Design and synthesis. Letters in Organic Chemistry 2006 Jan; 3(1):21-4.

190. Nguyen JH, Yamamoto S, Steers J, Sevlever D, Lin W, Shimojima N, Castanedes-Casey M, Genco P, Golde T, Richelson E, Dickson D, McKinney M, Eckman CB: Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice. Journal of Hepatology 44(6): 1105-1114, 2006.

191. Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Lavasseur BI, Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006 Jun 20; 24(18):2836-41.

192. Boules M, Iversen I, Oliveros A, Shaw A, Williams K, Robinson J, Fredrickson P, and Richelson E. The neurotensin receptor agonist NT69L suppresses sucrose-reinforced operant behavior in the rat. Brain Res 1127(1): 90-8, 2007.

193. Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, and Richelson E. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol 555(1): 30-36, 2007.

194. Bouras EP, Talley NJ, Camilleri M, Burton DD, Heckman MG, Crook JE, Richelson E. Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial. American Journal of Gastroenterology 103:2043-2050, 2008.

195. Corena-McLeod M, Oliveros A, Charlesworth C, Madden B, Liang Y-Q, Boules M, Shaw A, Williams K, Richelson E. Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression. Brain Research 1233: 8-19, 2008.

196. Liang Y, Boules M, Shaw A, Williams K, Fredrickson P, Richelson E. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Research 1231: 6-15, 2008.

197. Liang Y, Shaw A, Boules M, Briody S, Robinson J, Oliveros A, Blazar E, Williams K, Zhang Y, Carlier PR, Richelson E.: Antidepressant-like pharmacological profile of a novel triple re-uptake inhibitor, PRC200-SS. Journal of Pharmacology and Experimental Therapeutics 327: 573-583, 2008.

198. Roussy G, Dansereau MA, Dore-Savard L, Belleville K, Beaudet N, Richelson E, Sarret P: Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model. J Neurochem 105:1100-14, 2008.

Richelson-11

199. Lisanby SH, Husain MM, Rosenquist PB, Maixner D, Gutierrez R, Krystal A, Gilmer W, Marangell LB, Aaronson S, Daskalakis ZJ, Canterbury R, Richelson E, Sackeim HA, George MS: daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 34:522-34, 2009.

200. Roussy G, Dansereau M-A, Baudisson S, Ezzoubaa F, Belleville K, Beaudet N, Martinez J, Richelson E, and Sarret P. Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity. Molecular Pain art. no. 38. Mol Pain 5:38, Jul 6, 2009.

201. Boules M, Shaw A, Liang Y, Barbut D, Richelson E. NT69L, a novel analgesic, shows synergy with morphine. Brain Research. Brain Res 1294: 22-28, 2009.

202. Briody S, Boules M, Oliveros A, Fauq I, Richelson E. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. Behav Brain Res, 207:118-124, 2010.

203. Li Z, Boules M, William K, Peris J, Richelson E. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Research, 1311:28-36, 2010.

204. Boules M, Liang Y, Fauq I, Oliveros A, Wilson M, Khaniyev S, Williams K, Li Z, Qi Y, Katovich M, Richelson E. NT79: a Novel Neurotensin Analog with Selective Behavioral Effects. Brain Research,1308:35-46, 2010.

205. Lee MR, Hinton DJ, Song JY, Lee KW, Choo C, Johng H, Unal SS, Richelson E and Choi DS. Neurotensin receptor type 1 regulates ethanol intoxication and consumption in mice. Pharmacol Biochem Behav 95:235-241, 2010.

206. Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E. Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology 58(8):1199-1205, 2010.

207. Li Z, Liang Y, Boules M, Gordillo A, Richelson E. Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia. Neuropharmacology 58(7):1174-8, 2010.

208. Rossi GC, Matulonis JE, Richelson E, Barbut D, Pasternak GW. Systemically and topically active antinociceptive neurotensin compounds. J Pharmacol Exp Ther 2010 Sep; 334(3):1075-9.

209. Li Z, Boules M, Williams K, Gordillo A, Li S, Richelson E. Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia. Neurobiol Dis 2010 Nov; 40(2):467-77. Epub 2010 Jul 24.

210.Oliveros A, Heckman MG, Williams K, Boules M, Corena M, Richelson E. Sensorimotor gating of neurotensin-1 receptor and neurotensin-2 receptor null mice: Neurotensin-1 receptor is essential for d-amphetamine induced disruption of pre-pulse inhibition. Journal of Experimental Biology 2010 Dec 15; 213(Pt 24):4232-9.

211. Li Z, Boules M, Richelson E. NT69L blocks ethanol-induced increase of dopamine and glutamate levels in striatum of mouse. Neuroscience Letters, 2011 Jan 10;487(3):322-4. Epub 2010 Oct 23.

212. Lee MR, Hinton DJ, Unal SS, Richelson E, Choi D-S. Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2. Alcohol Clin Exp Res. 2011 Jan;35(1):99-107

213.. Boules MM, Oliveros A, Liang Y, Williams K, Shaw A, Robinson J, Fredrickson P, Richelson E. A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats. Neuropeptides. 2011 Feb;45(1):9-16.

214. Boules M, Johnston H, Tozy J, Smith K, Li Z, Richelson E. Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine. Behavioural Pharmacology. 2011 Sep;22(5-6):573-81.

215. Smith KE, Boules B, Williams K, Fauq Abdul H, Richelson E. The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia. Behavioural Brain Research

Behav Brain Res. 2011 Oct 31;224(2):344-9. Epub 2011 Jun 21. 216. Guillemette A, Dansereau M-A, Beaudet N, Richelson E, Sarret P. Intrathecal administration of NTS1

agonists reverses nociceptive behaviors in a rat model of neuropathic pain. European Journal of Pain. 2012 Apr; 16(4):473-84.

217. Zhu H-J, Appel DI, Grṻndemann D, Richelson E, Markowitz JS: Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res. 2012; 65(4):491-6.

218. Smith KE, Boules B, Williams K, Fauq Abdul H, Richelson E. NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain. Behav Brain Res. 2012 Apr 05. [Epub ahead of print]

219.Corena-McLeod M, Walss-Bass C, Oliveros A, Gordillo Villegas A, Ceballos C, Charlesworth CM, Madden B, Linser PJ, Van Ekeris L, Smith K, Richelson E. New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations. PLoS One. 2013 May 14;8(5):e52147. Print 2013.

Richelson-12

220. Huang P, Gebhart N, Richelson E, Brott TG, Meschia JF, Zubair AC. Cytotherapy. 2014 Jun 10. pii: S1465-3249(14)00605-7. doi: 10.1016/j.jcyt.2014.05.007. [Epub ahead of print]

221. Fredrickson P, Boules M, Stennett B, Richelson E. Neurotensin agonist attenuates nicotine potentiation to cocaine sensitization. Behav Sci (Basel). 2014 Jan 22;4(1):42-52. doi: 10.3390/bs4010042.

222. Boules M, Fredrickson PA, Richelson, E. An NTS2 analog enhances the analgesic effects of morphine in an animal model of persistent pain and does not exhibit tolerance. Open Pain Journal. 2015; 7(1):23-8.

223. Boules M, Netz R, Fredrickson PA, Richelson E: A neurotensin analog blocks cocaine-conditioned place preference and reinstatement. Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):236-9.

B. REVIEWS

1. Snyder, S.H. and Richelson, E.: Relationships Between the Conformation of Psychedelic Drugs and Their Psychotropic Potency. In Psychopharmacology, A Review of Progress, 1957-1967, D.H. Efron (Ed.), Public Health Service Publication No. 1836, pp.1199-1210, 1968.

2. Snyder, S.H. and Richelson, E.: Steric Models of Drugs Predicting Psychedelic Activity. In Psychotomimetic Drugs, D.H. Efron (Ed.), Raven Press, New York, pp. 43-66, 1970.

3. Snyder, S.H., Richelson, E., Weingartner, H., and L.A. Faillace: Psychotropic Methoxyamphetamines: Structure and Activity in Man. In Amphetamines and Related Compounds, E. Costa and S. Garattini (Eds.), Raven Press, New York, pp. 905-928, 1970.

4. Richelson, E.: Regulation of Catechol Synthesis in an Adrenergic Clone of Mouse Neuroblastoma. In Frontiers in Catecholamine Research, E. Usdin and S.H. Snyder (Eds.), Pergamon Press, Inc., New York, pp. 253-259, 1973.

5. Richelson, E. and M. Nirenberg: Tyrosine Hydroxylase (EC 1.14.3a) Assay. In Methods in Enzymology, S. Fleischer, L. Packer and E.W. Estabrook (Eds.), Academic Press, New York, Vol. XXXII, Part B, pp. 785-788, 1974.

6. Richelson, E.: Tissue Culture of the Nervous System: Applications in Neurochemistry and Psychopharmacology. In Handbook of Psychopharmacology, L.L. Iversen, S.D. Iversen and S.H. Snyder (Eds.), Plenum Publishing Co., New York, Vol. 1, pp. 101-135, 1975.

7. Richelson, E.: The Culture of Established Clones for Neurobiological Investigation. In Metabolic Compartmentation in the Brain, S. Berl, D.D. Clarke and D. Schneider (Eds.), Plenum Publishing Co., New York, pp. 305-326, 1975.

8. Richelson, E. and J. Elkes: A New Long-Acting Injectable Neuroleptic: Pipothiazine Palmitate. In Psychotherapeutic Drugs, E. Usdin and I. Forrest (Eds.), Marcel Dekker, Inc., New York, pp.957-970, 1977.

9. Fredrickson, P.A. and Richelson, E.: Dopamine and Schizophrenia: A Review. Journal of Clinical Psychiatry 40:399-405, 1979.

10. Richelson, E.: The Use of Cultured Cells in Neurobiological Studies. In International Review of Biochemistry, Volume 26, Neurochemistry and Biochemical Pharmacology, K.F. Tipton (Ed.), University Park Press, Baltimore, pp. 81-120, 1979.

11. . Taylor, J.E. and Richelson, E.: Receptor-Mediated Cyclic GMP Formation by an Adrenergic Clone (N1E-115) of Mouse Neuroblastoma. In Catecholamines: Basic and Clinical Frontiers (Proceedings of the 4th International Catecholamine Symposium), E. Usdin (Ed.), Pergamon Press, Inc., Oxford, pp.492-494, 1979.

12. Richelson, E.: Tricyclic Antidepressants and Neurotransmitter Receptors. Psychiatric Annals 9: 186-194, 1979.

13. Richelson, E. and R.A. Gorkin: Lithium Ion Entry into Cultured Cells of Neural Origin. In Biological Psychiatry Today, J. Obiols, C. Ballus, E.G. Monclus, J. Pujol (Eds.), Elsevier, Amsterdam, Vol. 2, pp. 1161-1166, 1979.

14. Richelson, E.: Psychotropic Drug Blockade of Histamine H1 Receptors. In Biological Psychiatry Today, J. Obiols, C. Ballus, E.G. Monclus, and J. Pujol (Eds.), Elsevier, Amsterdam, Vol. 1, pp. 106-109, 1979.

15. Richelson, E.: Tricyclic Antidepressants and Histamine H1 Receptors. Mayo Clinic Proceedings 54:669-674, 1979.

16. Rosenbaum, A.H., T. Maruta and Richelson, E.: Drugs That Alter Mood: I. Tricyclic Agents and Monoamine Oxidase Inhibitors. Mayo Clinic Proceedings 54:335-344, 1979.

17. Rosenbaum, A.H., T. Maruta and Richelson, E.: Drugs That Alter Mood: II. Lithium. Mayo Clinic Proceedings 54:401-407, 1979.

18. Trapp, B.D. and Richelson, E.: Usefulness of Rotation-Mediated Aggregating Cell Cultures. In Experimental and Clinical Neurotoxicology, P.S. Spencer and H.H. Schaumburg (Eds.), Williams and Wilkins, Maryland, pp. 803-819, 1980.

Richelson-13

19. Richelson, E.: Neuroleptics and Neurotransmitter Receptors. Psychiatric Annals, 10:21-40, 1980. 20. Richelson, E.: Binding to Intact Cultured Cells of Nervous Tissue Origin. In 1980 Short Course, Receptor

Binding Techniques. Society for Neuroscience, 218-240, 1980. 21. Richelson, E.: Psychotherapeutic Drugs, Histamine H1 and Muscarinic Acetylcholine Receptors. In

Psychopharmacology and Biochemistry of Neurotransmitter Receptors, H.I. Yamamura, R.W. Olsen and E. Usdin (Eds.), Elsevier North Holland, Inc., pp. 263-277, 1980.

22. Richelson, E.: Pharmacology of the Neuroleptics. In Neuropharmacology of Central and Behavioral Disorders, G.C. Palmer (Ed.), Academic Press, New York, pp. 123-147, 1981.

23. Taylor, J.E. and Richelson, E.: Histamine Receptors in Neural Tissue. In Neurotransmitter Receptors, Part 2, Series B, Vol. 10, of Receptors and Recognition, H.I. Yamamura and S. Enna (Eds.), Chapman and Hall, London, pp. 71-100, 1981.

24. Richelson, E.: Tricyclic Antidepressants: Interactions with Histamine and Muscarinic Acetylcholine Receptors. In Antidepressants: Neurochemical, Behavioral and Clinical Perspectives, S.J. Enna, J.B. Malick and Richelson, E. (Eds.), Raven Press, New York, pp. 53-73, 1981.

25. Richelson, E. and E. El-Fakahany: Commentary: The Molecular Basis of Neurotransmission at the Muscarinic Receptor. Biochem. Pharmacology, 30:2887-2891, 1981.

26. Richelson, E.: Management of the Depressed Patient: The Art and Science of Compliance. Part V: A Psychopharmacologic Perspective. In JCP Monograph Series, No. 1, Physicians Postgraduate Press, Memphis, pp. 23-26, 1982.

27. Richelson, E.: The Use of Tricyclic Antidepressants in Chronic GI Pain. Journal of Clinical Psychiatry, 43:8[Sec.2], 50-55, 1982.

28. Richelson, E. and E. El-Fakahany: Receptor Sensitivity Changes and the Actions of Some Psychotherapeutic Drugs. Mayo Clinic Proceedings, 57:576-582, 1982.

29. Richelson, E.: Pharmacology of Antidepressants in Use in the United States. Journal of Clinical Psychiatry, 43:11[Sec.2], 4-11, 1982.

30. Moyer, T.P., T. Maruta, Richelson, E. and J.W. Richardson: The Implications for Antidepressant Therapy of Measurement of Urinary MHPG. Mayo Clinic Proceedings, 57:665-667, 1982.

31. Richelson, E.: Antimuscarinic and Other Receptor Blocking Properties of Antidepressants. Mayo Clinic Proceedings, 58:40-46, 1983.

32. Richelson, E.: Antidepressants: Effects on Histamine and Muscarinic Receptors. In Clinical Pharmacology in Psychiatry, Bridging the Experimental-Therapeutic Gap, L.F. Gram, E. Usdin, S.G. Dahl, P. Krag-Sorensen, F. Sjoqvist and P.L. Morselli, eds., The Macmillan Press, Ltd., London, 288-300, 1983.

33. Gilbert, J. and Richelson, E.: Function of delta opioid receptors in cultured cells. Molecular and Cellular Biochemistry, 55:83-91, 1983.

34. Richelson, E.: Are receptor studies useful for clinical practice? Journal of Clinical Psychiatry, 44:9 [Sec. 2], 4-9, 1983.

35. Richelson, E.: Tricyclic Antidepressants: Therapy for ulcer and other novel uses. Modern Medicine, 51:74-86, 1983.

36. Richelson, E.: The newer antidepressants: structures, pharmacokinetics, pharmacodynamics and proposed mechanism of action. Psychopharmacology Bulletin, 20:213-223, 1984.

37. McKinney, M. and Richelson, E.: The coupling of the neuronal muscarinic receptor to responses. Annual Review of Pharmacology and Toxicology, 24:121-146, 1984.

38. Richelson, E.: Studying neurotransmitter receptors: binding and biological assay. In Neuroreceptors in Health and Disease, J. Marwaha and W. Anderson, eds., S. Karger, Basel, Monogr. Neural Sci. 10:4-19, 1984.

39. Richardson, J.W. and Richelson, E.: Antidepressants: A clinical update for medical practitioners. Mayo Clinic Proceedings, 59:330-337, 1984.

40. Richelson, E.: Psychopharmacology and the elderly: Interactions to watch for. Geriatrics, 39:30-42, 1984. 41. Richelson, E.: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.

Journal of Clinical Psychiatry, 45:331-336, 1984. 42. Richelson, E.: Schizophrenia: treatment. In Psychiatry, J. O. Cavenar, Jr., ed. J.B. Lippincott Company,

Philadelphia, Vol. 1, Chapter 55, 1985. 43. Richelson, E.: Pharmacology of neuroleptics in use in the United States. Journal of Clinical Psychiatry,

46:8[Sec 2], 8-14, 1985. 44. Richardson, J.W. III and Richelson, E.: Choosing and using antidepressants. Acute Care Medicine, 2:42-53,

1985.

Richelson-14

45. Richelson, E.: Tricyclic antidepressants. In Proceedings of the Space Adaptation Syndrome Drug Workshop, July 1983. (R.L. Kohl, ed.), p.59-67. Space Biomedical Research Institute, USRA Division of Space Biomedicine, Houston, 1985.

46. Black, J.L., Richelson, E., and J.W. Richardson, III: Antipsychotics - a clinical update. Mayo Clinic Proceedings, 60:777-789, 1985.

47. Richelson, E.: Histamine receptors, cyclic nucleotides and psychotropic drugs. In Frontiers in Histamine Research. C.R. Ganellin and J.-C. Schwartz, eds. Pergamon Press, Oxford, pp.237-247, 1985.

48. Richelson, E., S. Kanba and M. Pfenning: Influence of lithium ions on the guanylate cyclase system. In Drug Receptors and Dynamic Processes in Cells. J. S. Schou, A. Geisler and S. Norn, eds. Munksgaard International Publishers Ltd., Copenhagen, pp. 319-329, 1986.

49. Kanba, S. and Richelson, E.: Antidepressant interactions with neurotransmitter receptors in vitro: Prediction of potential side effects. In Receptor Binding in Drug Research, R. O'Brien, ed., Marcel Dekker, Inc., New York, pp. 429-447, 1986.

50. Black, J.L. and Richelson, E.: Prediction of side-effect profiles of antipsychotic drugs based on neuroreceptor data derived from human brain tissue. Mayo Clinic Proceedings 62:369-372, 1987.

51. Richelson, E. Antidepressants. In Encyclopedia of Neuroscience, Volume I. G. Adelman, ed. Birkhauser Boston, Cambridge, pp. 52-54, 1987.

52. Richelson, E., S. Kanba, K.S. Kanba, and M. Pfenning: Phosphoinositides and cyclic GMP in neuronal cells. In Synaptic Transmitters and Receptors. S. Tucek, ed. Academia, Prague, pp. 315-318, 1987.

53. Richelson, E.: The pharmacology of antidepressants. Psychopathology 20:suppl.1, 1-12, 1987. 54. Richelson, E.: La farmacologia de los antidepresivos. Psiquiatria 3:163-177, 1987. 55. Friedhoff, A.J., Pickar, D., Axelrod, J., Creese, I., Davis, K.L., Gallagher, D.W., Greengard, P., Housman,

D.,Maas, J.W.,Richelson, E., et al.: Neurochemistry and neuropharmacology. Schizophrenia Bull. 14:399-412, 1988.

56. Richelson, E.: Synaptic pharmacology of antidepressants: an update. McLean Hospital J.,XIII:67-88, 1988. 57. Richelson, E.: Neuroleptic binding to human brain receptors: relation to clinical effects. In The

Mesocorticolimbic Dopamine System, P.W. Kalivas and C.B. Nemeroff, eds. Ann. New York Acad. Sci. 537:435-442, 1988.

58. Larson, E.W. and Richelson, E.: Organic causes of mania. Mayo Clinic Proc. 63:906-912, 1988. 59. Richelson, E.: Antidepressants: pharmacology and clinical use. In Treatments of Psychiatric Disorders, First

Edition. T.B. Karasu, ed., A Task Force Report of the American Psychiatric Association, Washington, D.C. Vol. 3, pp 1773-1787, 1989.

60. McKinney, M. and Richelson, E.: Muscarinic receptor regulation of cyclic GMP and eicosanoid production. In The Muscarinic Receptors. J.H. Brown, ed.,The Humana Press, Inc., Clifton, NJ. pp. 309-339, 1989.

61. Richelson, E.: The use of cultured cells in the study of mood-normalizing drugs. Pharmacology and Toxicology 66 [Suppl.III]:69-75, 1990.

62. Richelson, E.: Closing lecture. Pharmacology and Toxicology 66 [Suppl.III]:144-148, 1990. 63. Pfenning, M.A. and Richelson, E.: Methods for studying receptors with cultured cells of nervous tissue

origin. In Methods in Neurotransmitter Receptor Analysis, H.I. Yamamura, S.J. Enna, and M.J. Kuhar (Eds.), Raven Press, New York, pp. 147-175, 1990.

64. Richelson, E.: Atypical antidepressants: pharmacokinetic and pharmacodynamic aspects. In Assistenza Territoriale Terapia Antidepressiva: Un Confronto di Esperienze Italiane ed Inglesi, C.L. Cazzullo and A.C. Altamura (Eds.), Idelson, Napoli, pp. 53-79, 1990.

65. Richelson, E.: Psychopharmacology, technology, and aging. Int. J. Technology Aging 3:19-28, 1990. 66. Richelson, E.: Antidepressants and brain neurochemistry. Mayo Clinic Proceedings 65:1227-1236, 1990. 67. Richelson, E.: Psychopharmacology of schizophrenia: past, present, and future. Psychiatric Annals 20:640-

644, 1990. 68. Richelson, E.: The pharmacology of three serotonin-selective drugs. Ann. Clin. Psychiatry 2:157-164, 1990. 69. Cohn, J., W. Katon, and Richelson, E.: Choosing the right antidepressant. Patient Care 24:88-116, 1990. 70. Kanba, S. and Richelson, E.: Interactions with psychotropic drugs. In Histaminergic Neurons: Morphology

and Function, T. Watanabe and H. Wada (Eds), CRC Press, Boca Raton, pp. 271-282, 1991. 71. Richelson, E.: Side effects of old and new generation antidepressants: a pharmacologic framework. J. Clin.

Psychiatry Monograph 9:13-19, 1991. 72. Richelson, E.: The molecular biology and neuropsychopharmacology of the muscarinic acetylcholine

receptors. In Annual Review of Psychiatry, Vol. 10, Tasman, A., S.M. Goldfinger (Eds.), APA Press, Inc., Washington, D.C., pp 423-433, 1991.

73. Richelson, E.: Biological basis of depression and therapeutic relevance. J. Clin. Psychiatry. 52 [Suppl]:4-10, 1991.

Richelson-15

74. Richelson, E.: Psychopharmacology of classical and atypical antipsychotics. Jpn. J. Psychopharmacol. 11:71-74, 1991.

75. Richelson, E.: Treatment of Schizophrenia. In Psychiatry - Revised Edition, R. Michels, ed. J.B. Lippincott Company, Philadelphia, Vol. 1, Chapter 55, 1992.

76. Richelson, E.: Muscarinic receptors: molecular biology and neuropsychopharmacology. In Treatment of Dementias, E. Meyer (Ed.), Plenum Publishing Corporation, New York, pp 3-17, 1992.

77. Richelson, E.: Histamine receptors in the central nervous system. In The Histamine Receptor, J.-C. Schwartz, H.L. Haas (Eds.), Alan R. Liss, Inc., New York, pp 271-295, 1992.

78. Richelson, E.: Regulation of neurotensin receptor expression and function in a neuronal model system. In: The Neurobiology of Neurotensin. Annals of the New York Academy of Sciences, 668:120-128, 1992.

79. Richelson, E.: Review of Antidepressants in the treatment of mood disorders. In Current Psychiatric Therapy, D.L. Dunner (Ed.), W.B. Saunders Company, Philadelphia, pp 232-239, 1993.

80. Richelson, E.: Treatment of acute depression. In Psychiatric Clinics of North America, Vol 16. W.B. Saunders Company, Philadelphia, pp. 461-478, 1993.

81. Richelson, E.: Preclinical pharmacology of antipsychotic drugs: relationship to efficacy and side effects. J. Clin. Psychiatry, Monograph series, 12, No.2:17-20, 1994.

82. Richelson, E.: The pharmacology of antidepressants at the synapse: focus on newer compounds. J. Clin. Psychiatry 55[Suppl. A] 34-39, 1994.

83. Richelson, E.: The Pharmacology of Antidepressants - Characteristics of the Ideal Drug. Mayo Clinic Proceedings 69:1069-1081, 1994.

84. Richelson, E., Preskorn, S.H., Feighner, J.P., Cunningham, L.A., Roose, S.P., and M.B. Keller: Antidepressant drug selection - criteria and options - Discussion. Journal of Clinical Psychiatry. 55(Suppl A):23-24, 1994.

85. Preskorn, S.H., Richelson, E., Roose, S.P., Feighner, J.P., Cunningham, L.A., Drevets, W.C.: The pharmacology of antidepressants at the synapse - focus on newer compounds - Discussion Journal of Clinical Psychiatry. 55(Suppl A):40, 1994.

86. Cunningham, L.A., Feighner, J.P., Roose, S.P., Richelson, E., Preskorn, S.H., and W.C. Drevets: The role of venlafaxine in rational antidepressant therapy - Discussion Journal of Clinical Psychiatry. 55(Suppl A):69-70, 1994.

87. Richelson, E., Drevets, W.C., and S.H. Preskorn: Geriatric depression - brain imaging correlates and pharmacologic considerations - Discussion. Journal of Clinical Psychiatry 55(Suppl A):82, 1994.

88. Richelson, E.: Cholinergic Transduction. In Psychopharmacology, The Fourth Generation of Progress, D. Kupfer and F. Bloom (Eds.), Raven Press, New York, pp 125-134, 1995.

89. Ascher, J.A., Cole, J.O., Colin, J.N., Feighner, J.P., Ferris, R.M., Fibiger, H.C., Golden, R.N., Martin, P., Potter, W.Z., Richelson, E., et al.: Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56:395-401, 1995.

90. Cusack, B., Richelson, E., Pang, Y.-P., Zaidi, J., and A. Kozikowski: Pharmacological studies on novel neurotensin mimetics: Discovery of a pharmacologically unique agent rationally designed according to the multiple template approach. In QSAR and Molecular Modeling: Concepts, Computational Tools and Biological Applications, F. Sanz, J. Giraldo, and F. Manaut (Eds.), Prous Science Publishers, Barcelona-Philadelphia, pp. 357-359, 1995

91. Le, F., Cusack, B. And Richelson, E.: The Neurotensin Receptor - Is There More Than One Subtype? Trends in Pharmacological Sciences 17:1-3, 1996.

92. Richelson, E.: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 57[suppl. 11]:4-11, 1996.

93. Richelson, E.: Synaptic effects of antidepressants. Journal of Clinical Psychopharmacology 16, Suppl. 2, S1-S7, 1996.

94. Richelson, E.: Synaptic effects of antidepressants - Commentary. Journal of Clinical Psychopharmacology 16, Suppl. 2, S7-S9, 1996.

95. Yamada, M. and Richelson, E.: Pharmacology of antidepressants in the elderly. In Handbook of Pharmacology of Aging, 2nd edition, J. Roberts, D.L. Snyder, and E. Friedman (Eds.), CRC Press, Inc., Boca Raton, pp.179-195, 1996.

96. Richelson, E.: Preclinical pharmacology of neuroleptics: focus on new generation compounds. Journal of Clinical Psychiatry 57 [suppl 11]:4-11, 1996.

97. Richelson, E.: The pharmacologic rationale behind antidepressant efficacy in severe depression, pp. 559-561. In: Controversies in the Diagnosis and Treatment of Severe Depression. J. Clin. Psychiatry 57:554-561, 1996.

Richelson-16

98. Richelson, E.: Review of antidepressants in the treatment of mood disorders. In Current Psychiatric Therapy II, D.L. Dunner (Ed.), W.B. Saunders Company, Philadelphia, pp.286-295, 1997.

99. Richelson, E.: Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clinic Proceedings 72:835-847, 1997...\..\Documents\Papers PDF\Richelson Mayo Clinic Proc Review 1997.pdf

100. Hong, F., Cusack, B., Fauq, A., and Richelson, E.: Peptidic and non-peptidic neurotensin analogs. Current Medicinal Chemistry 4:421-434, 1997.

101. Richelson, E.: Weight gain on SSRIs: a paradox? Primary Psychiatry 5: 40-41, 1998. 102. Valentine, A.D., Meyers, C.A., Kling, M.A., Richelson, E., Hauser, P. Mood and cognitive side effects of

interferon- therapy. Seminars in Oncology, 25, No. 1, Suppl. 1: 39-47, 1998. 103. Richelson, E.: Serotonin: and what about its side effects? Depression and Anxiety 7, Suppl.1:18-20, 1998. 104. Richelson, E.: Pharmacokinetic interactions of antidepressants. Journal of Clinical Psychiatry 59, Suppl.

10:22-26, 1998. 105. Richelson, E.: Mood Disorders. In Conn's Current Therapy 1999, R. Rakel (Ed.), W.B. Saunders Company,

Philadelphia, pp.1135-1145, 1999. 106. Richelson, E. Antidepressants. In Encyclopedia of Neuroscience, 2nd enlarged and revised edition, G.

Adelman and B.H. Smith, eds. Elsevier Science B.V., New York, pp. 97-99, 1999. 107. Richelson, E.:Basic neuropharmacology of antidepressants relevant to the pharmacotherapy of depression.

Clinical Cornerstone 4:17-30, 1999. 108. Richelson, E.: Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry 60,

Suppl. 10:5-14, 1999. 109. Richelson, E.: Mood Disorders. In Conn's Current Therapy 2000, R. Rakel (Ed.), W.B. Saunders Company,

Philadelphia, pp.1107-1117, 2000. 110. Leonard, B. and Richelson, E.: Synaptic effects of antidepressants: relation to their therapeutic and adverse

effects. In Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice, Buckley, P.F. and Waddington, J.L. (Eds.) Butterworth-Heinemann, Oxford, pp 67-84, 2000.

111. Tyler-McMahon, B.M., Boules, M., Richelson, E.: Neurotensin: Peptide for the next millennium. Regulatory Peptides 93:125-136, 2000.

112. Richelson, E.:The pharmacology of antidepressants. Mayo Clinic Proceedings 76: 511-527, 2001. 113. Richelson, E.:Pharmacology of antidepressants: clinical relevance of effects on neurotransmitter systems

and their receptors. In Focus on Psychiatry, Antidepressants: Selectivity or Multiplicity, den Boer, J.A. and Westenberg, H.G.M. (Eds.) Benecke N.I., Amsterdam, pp. 43-59, 2001.

114. McMahon, B.M., Boules, M., Warrington, L., and Richelson, E.: Neurotensin analogs: Indications for use as potential antipsychotic compounds. Life Sciences 70:1101-1119, 2002.

115. Richelson, E.: The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacology Bulletin 36:133-149, 2002.

116. Richelson, E., Boules, M., and Fredrickson, P.: Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. Life Sciences 73:679-690, 2003.

117. Boules, M., Fredrickson, P., and Richelson, E.: Brain penetrating neurotensin analog. Life Sciences 73:2785-2792, 2003.

118. Richelson, E: Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Journal of Clinical Psychiatry 64 Suppl 13:5-12, 2003.

119. Richelson, E.: Antidepressants: mechanisms of action. In Preventative Pharmacotherapy of Headache Disorders, Olsen, J., Silberstein, S.D., and Felt-Hansen, P. (Eds.). Oxford University Press, Oxford, pp. 112-120, 2004.

120. Boules, M., Richelson, E.: NTS1 neurotensin receptor. In xPharm (2004);Executive Editors: S.J.. Enna and David B. Bylund; Publisher, Elsevier Inc., New York. http://www.xpharm.com/citation?Article_ID=146

121. Boules, M., Richelson, E.: NTS2 neurotensin receptor. In xPharm (2004);Executive Editors: S.J.. Enna and David B. Bylund; Publisher, Elsevier Inc., New York. http://www.xpharm.com/citation?Article_ID=147

122. Boules, M., Richelson, E.: NTS3 neurotensin receptor. In xPharm (2004);Executive Editors: S.J.. Enna and David B. Bylund; Publisher, Elsevier Inc., New York. http://www.xpharm.com/citation?Article_ID=42295

123. Richelson, E.: Psychotropic drugs: receptor affinities and clinical effects. In The History of Psychopharmacology and the CINP - As Told in Autobiography, Volume 4, Ban, T., Healy, D., Shorter, E. (Eds.). Animula Publishing House, Budapest, pp. 655-660, 2004.

124. Boules, M., Fredrickson, P., Richelson, E.: Neurotensin agonists as an alternative to antipsychotics. Expert Opinion on Investigational Drugs 14:359-69, 2005.

Richelson-17

125. Fredrickson, P., Boules, M., Lin, S.-C., Richelson, E.: Neurobiological basis of nicotine addiction and psychostimulant abuse-A role for neurotensin? Psychiatr Clin North Am 28:737-51, 2005.

126. Richelson, E: Neuroleptics, neurotransmitters, and neuropsychopharmacology. In The Neurotransmitter Era in Neuropsychopharmacology, Ban, T.A., Udabe, R.C. (Eds.). Editorial Polemos, Buenos Aires, pp. 153-160, 2006.

127. Boules, M., Fredrickson, P., Richelson, E.: Bioactive Analogs of Neurotensin. Peptides 27:2523-2533, 2006. 128. Boules M, Shaw A, Fredrickson P, and Richelson E.: Neurotensin agonists: potential in the treatment of

schizophrenia. CNS Drugs 21(1): 13-23, 2007. 129. Shaw A, Boules M, and Richelson E.: Triple reuptake inhibitors. Current Psychiatry 6:31-42, 2007. 130. Richelson, E.: Action of antidepressant and other drugs on norepinephrine systems. In Brain

Norepinephrine: Neurobiology and Therapeutics, Ordway, G.A., Schwartz, M., and Frazer, A. (Eds.). Cambridge University Press, Cambridge, pp. 515-534, 2007.

131. Richelson, E.: Mechanisms of action of repetitive transcranial magnetic stimulation (rTMS) and vagus nerve stimulation (VNS). Psychiatr Ann 2007 Mar; 37(3):181-7.

132. CME Institute of Physicians Postgraduate Press Inc. Transcranial magnetic stimulation: potential new treatment for resistant depression. J Clin Psychiatry Feb; 68(2):315-30, 2007.

133. Liang Y, Richelson E. Triple reuptake inhibitors: Next-generation antidepressants. Primary Psychiatry 2008 Apr; 15(4):50-6.

134. Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? Journal of Clinical Psychiatry, 2010 Sep; 71(9):1243-44.

135.Fredrickson PA, Richelson E. Neuropharmacology of mental illness. In: Pandi-Perumal SR; Kramer M editor. Sleep and mental illness. Cambridge; New York: Cambridge University Press; 2010. (Cambridge Medicine.). p. 1-6.

136. Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL. Considerations on Safety Concerns About Citalopram Prescribing. Mayo Clin Proc. 2012 Sep 20.

137. Krystal AD, Richelson E, Roth T. Review of the histamine system and the clinical effects of H(1) antagonists: Basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev. 17:263-272, 2013.

138. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013:1-10.

139.Boules M, Li Z, Smith K, Fredrickson P, Richelson E. Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne). 2013 Mar 22;4:36. doi: 10.3389/fendo.2013.00036. eCollection 2013.

140.Boules MM, Fredrickson P, Muehlmann AM, Richelson E. Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders. Behav Sci (Basel). 2014 Jun 13;4(2):125-53. doi: 10.3390/bs4020125.

C. EDITORIALS

1. Richelson, E.: Spinal Opiate Administration for Chronic Pain: A Major Advance in Therapy. Mayo Clinic

Proceedings, 56, 523, 1981.

2. Richelson, E.: Tricyclic Antidepressants: Drugs for Other Diseases. Archives of Internal Medicine 142, 231,

1982.

3. Richelson, E.: Overview: Where are all the novel antidepressants. Current Opinion in Investigational Drugs 2,

256-258, 2001.

4. Richelson, E.: Reflections on “Biological Researches on the Mechanism of Mood Disorder.” In Recent

Advances in the Research of Affective Disorder in Japan, Okuma, R., Kanba, S., and Inoue, Y. (Eds.)

Elsevier, Amsterdam, pp. 39-41, 2003.

5. Richelson, E. and Elliott, D.S.: Advances in medical management of overactive bladder. Mayo Clinic

Proceedings 78: 681-683, 2003.

Richelson-18

D. BOOKS

1. Antidepressants: Neurochemical, Behavioral and Clinical Perspectives, S. J. Enna, J.B. Malick and Richelson, E. (Eds.), Raven Press, New York, 1981.

2. Herbal Medicines for Neuropsychiatric Diseases, S. Kanba and Richelson, E. (Eds.), Seiwa Shoten Publishers, Tokyo, 1999.

E. LETTERS TO THE EDITOR

1. Kanba, S. and Richelson, E.: Lithium inhibits muscarinic receptor mediated cyclic GMP formation. New England Journal of Medicine 310, 989-990, 1984.

2. Kanba, S. and Richelson, E.: Pharmacological properties of tricyclic antidepressants and the treatment of somatic disorders. American Journal of Psychiatry 141, 724, 1984.

3. Lenox, R.H., R.J. Hitzemann, Richelson, E., and J.R. Kelsoe, Jr.: Failure to Confirm Muscarinic Receptors on Skin Fibroblasts. New England Journal of Medicine 312, 861, 1985.

4. Lin, S.-C., T. Hsu, P.A. Fredrickson, and Richelson, E.: Yohimbine and tranylcypromine-induced postural hypotension. American Journal of Psychiatry 144, 119, 1987.

5. Richelson, E.: Mesoridazine and Thioridazine. Journal of Clinical Psychiatry 48, 344, 1987. 6. Richelson, E., Boules, M.M., Fredrickson, P.A.: Neurotensin receptor agonists and antagonists for

schizophrenia. American Journal of Psychiatry 162:633-634, 2005. 7. Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL. In

reply. Mayo Clin Proc. 2013 Apr; 88(4):420. 8. Fredrickson P, Boules M, Richelson E. Neurotensin agonists in the regulation of food intake. Int J Obes (Lond).

2013 Jul 17. [Epub ahead of print]

F. ABSTRACTS

1. Amano, T., Richelson, E. and M. Nirenberg: Neurohormone Synthesis By Different Clones of Neuroblastoma. Federation Proceedings 30, 1085, 1971.

2. Richelson, E.: Regulation of Tyrosine Hydroxylase Activity in a Clone of Mouse Neuroblastoma. Federation Proceedings 31, 898, 1972.

3. Richelson, E.: Stimulation of Tyrosine Hydroxylase Activity in a Clone of a Mouse Neuroblastoma by Dibutyryl Cyclic AMP. Fifth International Congress on Pharmacology 193, 1972.

4. Richelson, E.: Regulation of Tyrosine Hydroxylase Activity in Mouse Neuroblastoma Clone N1E-115. Life Sciences 13, No. 9: CXXXVII-CXXXVIII, 1973.

5. Tuttle, J. and Richelson, E.: Regulation of Electrical Activity in Mouse Neuroblastoma Clone N1E-115. The Society of Neurosciences, Fourth Annual Meeting 455, 1974.

6. Richelson, E.: Studies on the Transport of L-Tyrosine Into an Adrenergic Clone of Mouse Neuroblastoma. The Pharmacologist, 16, No. 2, 199, 1974.

7. Honegger, P. and Richelson, E.: Neurochemical Studies on Aggregating Cultures of Mouse Brain. Federation Proceedings 34, No. 3, 773, 1975.

8. Honegger, P. and Richelson, E.: Neurochemical Studies on Aggregating Cultures of Three Regions of Rat CNS. American Society for Neurochemistry, 7th Annual Meeting 177, 160, 1976.

9. Richelson, E.: Properties of Tyrosine Hydroxylation in Living Mouse Neuroblastoma Cells. Federation Proceedings 35, 267, 1976.

10. Richelson, E.: Antipsychotic Drugs Block the Muscarinic Acetylcholine Receptor in Living Mouse Neuroblastoma Cells. C.I.N.P. 10th Congress 230, 161, 1976.

11. Richelson, E.: Studies on Lithium Ion Transport Into Cultured Mouse Neuroblastoma Cells. The Pharmacologist, 18, No. 2, Abstract 88, 129, 1976.

12. Divinetz-Romero, S. and Richelson, E.: Antidepressant Drugs Block Muscarinic Acetylcholine Receptor Mediated Formation of Cyclic GMP in Cultured Mouse Neuroblastoma Cells. Federation Proceedings, 36, No. 3, 290, 1977.

13. Riley, D. and Richelson, E.: Effects of Ethanol on Prostaglandin E1 (PGE1)-Stimulated cAMP Formation in Mouse Neuroblastoma Cells. Federation Proceedings, 36, No. 3, 331, 1977.

14. Richelson, E.: Antipsychotic Drugs Block Muscarinic Acetylcholine Receptor-Mediated Formation of Cyclic GMP in Cultured Mouse Neuroblastoma Cells. Federation Proceedings, 36, No. 3, 750, 1977.

15. Richelson, E. and S. Romero: Muscarinic Receptor-Mediated cGMP Formation: Block by Psychotropic Drugs. Trans. American Society for Neurochemistry, 8, No. 2, 123, 1977.

16. Honegger, P. and Richelson, E.: Neurotransmitter Synthesis by Aggregating Cultures of Rat CNS. Transactions of the American Society for Neurochemistry, 8, No. 2, 162, 1977.

17. Richelson, E. and P. Honegger: Neurotransmitter Synthesis, Storage and Release by Aggregating Cultures of Rat CNS. Society for Neuroscience, 3, Abstract 1314, 412, 1977.

18. Trapp, B.D., P. Honegger, H. deF. Webster and Richelson, E.: Fine Structure of Mechanically Dissociated Rat CNS Aggregating Cell Cultures. Soc. Neuroscience, 3, Abstract 1693, 529, 1977.

Richelson-19

19. Richelson, E. and F.G. Prendergast: Muscarinic Receptor Function in Cultured Nerve Cells, Ion Dependence and Effects of Local Anesthetics. The Pharmacologist, 19, No. 2, 198, 1977.

20. Richelson, E.: Histamine (H1) Receptor-Mediated Cyclic GMP Formation by Mouse Neuroblastoma Cells. Federation Proceedings, 37, No. 3, Abstract 939, 390, 1978.

21. Richelson, E.: Regulation of Muscarinic Receptor Effects by Cultured Nerve Cells. Transactions of the American Society for Neurochemistry, 9, No. 1, Abstract 151, 123, 1978.

22. Gorkin, R.A. and Richelson, E.: Lithium Accumulation by Cultured Mouse Neuroblastoma Cells. Transactions of the American Society for Neurochemistry, 9, No. 1, Abstract 91, 94, 1978.

23. Richelson, E.: Tricyclic Antidepressants Block Histamine H1 Receptors of Cultured Nerve Cells. C.I.N.P., 11th Congress, 1978.

24. Taylor, J.E. and Richelson, E.: Desensitization of Histamine H1 Receptors on Mouse Neuroblastoma Cells. The Pharmacologist, 20, No. 3,176, 1978.

25. Richelson, E.: Psychotropic Drug Blockade of Histamine H1 Receptors. Second World Congress of Biological Psychiatry, Abstract 349, 83, 1978.

26. Richelson, E. and R.A. Gorkin: Lithium Ion Entry Into Cultured Nerve Cells. Second World Congress of Biological Psychiatry, Abstract 601, 133, 1978.

27. Gorkin, R.A. and Richelson, E.: Lithium Accumulation by Cultured Glioma Cells. Second World Congress of Biological Psychiatry, Abstract 606, 134, 1978.

28. Knodel, E.L. and Richelson, E.: Opiate Receptors in Aggregating Cell Cultures of Embryonic Rat Brain. Society for Neuroscience, 4, 134, 1978.

29. Gorkin, R.A. and Richelson, E.: Lithium Transport by Cultured Glioma Cells. Society of Biological Psychiatry, Abstract 27, 62, 1979.

30. Richelson, E.: Psychotherapeutic Drugs, Histamine H1 and Muscarinic Acetylcholine Receptors. Society of Biological Psychiatry, Abstract 44, 81, 1979.

31. Taylor, J.E. and Richelson, E.: Regulation of Histamine H1 Receptors on Mouse Neuroblastoma Cells. Transactions of the American Society for Neurochemistry, 10, 190, 1979.

32. Taylor, J.E. and Richelson, E.: Muscarinic Acetylcholine Receptors: Short- and Long-Term Regulation of Sensitivity. The Pharmacologist 156, 1979.

33. Taylor, J.E. and Richelson, E.: Histamine H1 Receptors on Neuroblastoma Cells: Short- and Long-Term Regulation of Sensitivity. Society for Neuroscience, 5, 747, 1979.

34. Petersen, R.C. and Richelson, E.: Anticholinergic Activity of Imipramine Analogs at Muscarinic Receptors of Cultured Mouse Neuroblastoma Cells. Society for Neuroscience, 5, 659, 1979.

35. Knodel, E.L. and Richelson, E.: Methionine-enkephalin-like immunoreactivity in Fetal Rat Brain Cells in Aggregating Culture and in Mouse Neuroblastoma Cells. Society for Neuroscience, 5, 531, 1979.

36. Richelson, E.: Psychotropic Drugs and Histamine H1 Receptors of Cultured Mouse Neuroblastoma Cells. Psychopharmacology Bulletin, 16, No. 1, 38, 1980.

37. Taylor, J.E., T. Yaksh and Richelson, E.: Regional Distribution of Histamine H1 Receptors in the Brain and Spinal Cord of the Cat. Fed. Proceedings, 39, No. 3, Abstract 636, 389, 1980.

38. Richelson, E.: Tricyclic Antidepressants and Histamine Receptors. Transactions of the American Society of Neurochemistry, 11, No. 1, Abstract 284, 209, 1980.

39. Wastek, G.J., J.R. Lopez and Richelson, E.: Measurement of a Receptor-Mediated Change in the Membrane Potential of Mouse Neuroblastoma Cells Using ([3H]TPP). Federation Proceedings, 39, No. 3, Abstract 1404, 533, 1980.

40. Wastek, G.J., T.L. Yaksh and Richelson, E.: Characterization of [3H]Leu-Enkephalin Binding in Cat CNS: Effects of Lumbar Rhizotomy. Society for Neuroscience, 6, 525, 1980.

41. Taylor, J.E. and Richelson, E.: High Affinity Binding of [3H]Doxepin to Rat Brain Tissue. Society for Neuroscience, 6, 237, 1980.

42. El-Fakahany, E. and Richelson, E.: Involvement of Calcium Channels in Short-Term Desensitization of Receptor-Mediated Cyclic GMP Formation in Mouse Neuroblastoma Cells. Society for Neuroscience, 6, 215, 1980.

43. El-Fakahany, E. and Richelson, E.: Differential Effect of a Lanthanide on Binding of Muscarinic Receptor Agonists and Antagonists. The Pharmacologist, 22, No. 3, Abstract 46, 165, 1980.

44. Richelson, E. and J. Carlson: In Vitro Red Blood Cell Lithium Ratios for a Randomly Selected Population of Blood Donors. Society of Biological Psychiatry, Abstract 28, 60, 1980.

45. Gilbert, J., E. Knodel, S. Stenstrom and Richelson, E.: Synthesis and Function of Met5-enkephalin in a Mouse Neuroblastoma Clone. Transactions of the American Society for Neurochemistry, 12, No. 1, Abstract 56, 97, 1981.

46. El-Fakahany, E. and Richelson, E.: 2-Halogenoethylamines and Ca2+ Channels of Muscarinic Receptors. Transactions of the American Society for Neurochemistry, 12, No. 1, Abstract 134, 136, 1981.

47. Richelson, E.: Anticholinergic Properties and Tricyclic Antidepressants. American Psychiatric Association, 134th Annual Meeting, Syllabus and Scientific Proceedings, Abstract 22B, 50, 1981.

48. Snider, R. M., Richelson, E. and J.R. Blinks: Use of Aequorin to Determine Changes in Intracellular Free Ca++ in Murine Neuroblastoma Clone N1E-115 Cells. Society for Neuroscience, 8, 124, 1982.

Richelson-20

49. Turner, S.T., M. Johnson, Richelson, E. and C. Sing: Maximal Rate of Sodium-Lithium Countertransport (Na-Li CNT) in Red Blood Cells (RBC's) From Randomly-Selected Blood Donors and Patients with Essential Hypertension (EH). 36th Annl Fall Conf and Scientific Sessions, Council High Blood Pressure Research, Am Heart Association, 1982.

50. Turner, S.T., M. Johnson, Richelson, E. and C. Sing: Maximal Rate of Sodium-Lithium Countertransport (Na-Li CNT) in Red Blood Cells (RBC's) From Randomly-Selected Blood Donors and Patients with Essential Hypertension (EH). Clinical Research, 30:734A, 1982.

51. Oakes, S.G., S. Taylor, and Richelson, E.: Demonstration of a Histamine (H1) Receptor-Mediated Cyclic GMP-Related Hyperpolarization of the Membrane of Murine Neuroblastoma Cells. Federation Proceedings, 42, No. 4, Abstract 3599, 906, 1983.

52. Snider, R.M., M. McKinney, J.W. Fenton, II, and Richelson, E.: Thrombin Binding and Effects in Intact Murine Neuroblastoma N1E-115 Cells. Transactions of the American Society for Neurochemistry, 14, No. 1, Abstract 145, 156, 1983.

53. Snider, R.M. and Richelson, E.: Bradykinin Receptor Binding and Biological Activity in Murine Neuroblastoma Clone N1E-115 Cells. Soc. for Neuroscience, 9, Part 1, Abstract 52.8, 172, 1983.

54. McKinney, M., S. Stenstrom and Richelson, E.: Effect of Short-Term Desensitization on Muscarinic Receptor Binding in Intact Murine Neuroblastoma Cells (Clone N1E-115). Society for Neuroscience, 9, Part 1, Abstract 169.1, 581, 1983.

55. Richelson, E., R.M. Snider, M. McKinney and C. Forray: Neurotransmitter Receptor-Mediated Cyclic GMP Formation: A New Hypothesis Implicating the Involvement of Phospholipase A2 and Arachidonic Acid Metabolites. Soc. for Neuroscience, 9, Part 1, Abstract 135.10, 458, 1983.

56. C. Forray and Richelson, E.: Glucocorticoids Enhance PGE1-Stimulated Cyclic AMP Formation in Cultured Murine Neuroblastoma Cells (Clone N1E-115). Society for Neuroscience, 9, Part 1, Abstract 166.12, 574,1983.

57. McKinney, M., R.M. Snider, J. W. Fenton, II, and Richelson, E.: Thrombin Binding and Effects in Intact Murine Neuroblastoma N1E-115 Cells. Fed. Proc., 42, No. 4, Abstract 3462, 883, 1983.

58. Kanba, S., and Richelson, E.: Histamine H2 Receptors of Dissociated Cells from Guinea Pig Hippocampus. Trans. Am. Soc. for Neurochemistry, 14, No. 1, Abstract 144, 156, 1983.

59. Richelson, E., J. Carlson, K. Snyder and C. Sing: In Vitro Lithium Ion Ratios (LRS) for 501 Randomly Selected Blood Donors. Society of Biological Psychiatry, Abstract 110, 144, 1983.

60. Kanba, S. and Richelson, E.: Lithium Affects Muscarinic Function. Society of Biological Psychiatry, Abstract 58, 100, 1984.

61. McKinney, M., S. Stenstrom, and Richelson, E.: Characterization of M1 and M2 Muscarinic Receptor Subtypes in Murine Neuroblastoma Clone N1E-115 Cells. Society for Neuroscience 10, Part 2, Abstract 275.2, 934, 1984.

62. Gilbert, J.A., M. McKinney, and Richelson, E.: Neurotensin Stimulates Cyclic GMP Formation in Neuroblastoma Clone N1E-115 and Rat Cerebellum. Society for Neuroscience 10, Part 1, Abstract 114.8, 378, 1984.

63. Forray, C., M. McKinney, and Richelson, E.: Characterization of Phospholipases Involved in Receptor-Mediated Arachidonic Acid Release. Soc. Neurosci. 10, Part 2, Abstract 341.14, 1184, 1984.

64. McKinney, M. and Richelson, E.: The effector for muscarinic receptors in N1E-115 neuroblastoma cells. The Second International Symposium on Subtypes of Muscarinic Receptors, Sponsored by Boston University School of Medicine, Abstract 13,1985.

65. Kanba, S., M. Pfenning and Richelson, E.: Li+ inhibits receptor-mediated cyclic GMP formation (guanylate cyclase system). Annual Meeting of the American College of Neuropsychopharmacology, Abstract, 161, 1985.

66. Kanba, K.S., S. Kanba, H. Okazaki and Richelson, E.: [3H]Neurotensin binding in human brain. Annual Meeting of the American College of Neuropsychopharmacology, Abstract, 162, 1985.

67. Kanba, K.S. and Richelson, E.: A comparison of the stimulation of inositol phospholipid hydrolysis and of cyclic GMP formation by neurotensin and its analogs in neuroblastoma clone N1E-115. Society for Neuroscience 12, 826, 1986.

68. Gilbert, J.A. and Richelson, E.: Rapid degradation of neurotensin by neuroblastoma clone N1E-115. Society for Neuroscience 12, 762, 1986.

69. Kanba, S., K.S. Kanba, and Richelson, E.: Effects of the protein kinase C activator, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), on muscarinic (M1) receptor-mediated inositol phosphate release and cyclic GMP formation in murine neuroblastoma cells (clone N1E-115). Society for Neuroscience 12, 572, 1986.

70. Wander, T.J., A. Nelson, H. Okazaki and Richelson, E.: Antagonism by antidepressants and neuroleptics of serotonin S1 and S2 receptors of normal human brain in vitro. The Pharmacologist 28, 90, 1986.

71. Richelson, E., M. McKinney, C. Forray, S. Kanba and K. Kanba: Phosphoinositides and cyclic GMP in neuronal cells. European Society for Neurochemistry, Abstract, 103, 1986.

72. Gilbert, J.A. and Richelson, E.: Desensitization of neurotensin receptor-mediated cyclic GMP formation in neuroblastoma clone N1E-115. Society for Neuroscience 13, 1523, 1987.

Richelson-21

73. Al-Rodhan, N.R.F., Richelson, E., J.A. Gilbert, E.W. Larson, and T.L. Yaksh: Structure-activity relationship of neurotensin (NT)-mediated antinociception in the periaqueductal gray (PAG) of the rat. FASEB J. 2, A785, 1988.

74. Van Dyke, R.A., D. Rademacher, R.M. Nelson, and Richelson, E.: Effect of halothane on hepatic alpha1-adrenoceptor ligand binding. FASEB J. 2, A1395, 1988.

75. Donato Di Paola, E., D. McCormick, and Richelson, E.: Effects of neurotensin and some analogs on blood pressure in rat. Society for Neuroscience, 14,150, 1988.

76. Surichamorn, W., C.L. Amrhein, M. McKinney, Richelson, E., S. Stenstrom, C.L. Cioffi, and E.E. El-Fakahany: Anomalous pirenzepine-induced antagonism of muscarinic responses. The Pharmacologist 30, A183, 1988.

77. Gilbert, J.A., D.J. McCormick, and Richelson, E.: Structure-activity studies of novel neurotensin(8-13) analogs. Am. Soc. Neurochemistry. Trans. Am. Soc. Neurochem. 20: 236, 1989.

78. Donato di Paola, E. and Richelson, E.: Down-regulation of neurotensin receptors by [D-LYS8]NT(8-13) in neuroblastoma clone N1E-115. FASEB J. 3, A288, 1989.

79. Fredrickson, P.A., T.C. Merritt, and Richelson, E., E.J. Bergstralh, K.P. Offord, J. Kaplan, and R.J. Ivnik: Aspartame's effect on sleep and wakefulness measures. Sleep Research 18, 51, 1989.

80. Kanba, S., Yagi, G., Kato, R., and Richelson, E.: An important role of lithium ion entry through the sodium channel during depolarization in transmembrane control. Neurochem. Res. 14:803, 1989.

81. Kanba, S., Yagi, G., Nahaki, E., Oguchi, E., and Richelson, E.: Neuropharmacology of zotepine: a potent D2 and 5-HT2 blocker. Neurochem. Res. 15:366, 1990.

82. Bolden, C.P., McCormick, D.J., Krco, C., and Richelson, E.: Characterization of monoclonal antibodies against an m1 muscarinic receptor peptide. Soc. Neurosci. 16:203, 1990.

83. Kanba, S., Yagi, G., Nakaki, T., Takamiya, M., Inomata, T., Ishizuki, T., Shintani, F., Oguchi, E., Richelson, E., and Kato, R.: Neuropharmacology of zotepine, an antimanic drug; a potent blocker of D2 and 5-HT2 receptors of human brain. 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Abstracts, Vol. II, p. 281, 1990.

84. Richelson, E.: Clinical significance of receptor effects of antidepressants. Clinical Neuropharmacology 13:[Suppl 2] 323-324, 1990.

85. Richelson, E., Stanton, T., Cusack, B., Watson, M., Bolden, C.: Ontogeny of neurotensin receptors in a neuroblastoma clone N1E-115. Trans. Am. Soc. Neurochem. 22:185, 1991.

86. Bolden, C.P., Cusack, B., and Richelson, E.: Clozapine is a potent and selective antagonist at the five cloned human muscarinic cholinergic receptors. FASEB J. 5:A487, 1991.

87. Cusack, B.M., Stanton, T., Bolden, C. and Richelson, E.: Antagonism by antidepressants and antihistaminics at the 5 cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells. FASEB J. 6: A1880, 1992.

88. Yamada, M. Yamada, Mi.,Cusack, B., and Richelson, E.: Regulation of neurotensin receptor by receptor mediated cGMP formation in N1E-115 neuroblastoma cells. CINP XVIIIth Congress. Clin. Neuropharmacol. 15:[Suppl 1,PTB] 501, 1992.

89. Cusack, B. and Richelson, E.: A method for radioligand binding assays using a robotic workstation. 5th Swiss Workshop of Methodology in Receptor Research, 4, 1992.

90. Yamada, M., Yamada, Mi., and Richelson, E.: Temperature dependence of neurotensin receptor desensitization, resensitization, down-regulation, and its recovery in N1E-115 neuroblastoma cells. The Pharmacologist 34:200, 1992.

91. Yamada, Mi., Yamada, M., and Richelson, E.: Cyclic guanosine 3',5'-monophosphate formation and nitric oxide in neuroblastoma clone N1E-115 cells. The Pharmacologist 34:141, 1992.

92. Bolden, C. and Richelson, E.: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. The Pharmacologist 34:154, 1992.

93. Yamada, M., Yamada, Mi., and Richelson, E.: Effects of the aminosteroid U-73122 on neurotensin or muscarinic receptor mediated cGMP formation and PPI hydrolysis in N1E-115 cells. Soc. Neurosci. 18:1006, 1992.

94. Richelson, E., Watson, M., Yamada, M., Yamada, Mi., Cusack, B., Veverka, K., and C. Bolden-Watson. The rat neurotensin receptor expressed in Chinese hamster ovary cells mediates the release of inositol phosphates and the stimulation of cyclic AMP but not the inhibition of cyclic AMP. Second NIMH Conference on Molecular Neurobiology, p. 49, 1992.

95. Cusack, B.M. and Richelson, E.: Antagonism by antidepressants and some of their metabolites at 7 neurotransmitter receptors of normal human brain. FASEB J. 7:A394, 1993.

96. Yamada, M, Yamada, Mi., and Richelson, E.: Mechanistic studies of neurotensin (NT) receptor down-regulation in N1E-115 cells. Trans. Soc. Neurochemistry 24:180, 1993.

97. Yamada, M., Watson, M.A., Bolden-Watson, C., Yamada, Mi., and Richelson, E.: Expression of mRNA encoding the neurotensin receptor in human brain. Biol. Psychiatry. 33:135A, 1993.

98. Bolden-Watson, C., Watson, M., and Richelson, E.: Effect of the neurotensin receptor antagonist SR48692 on the expression of neurotensin and neurotensin receptor mRNA in rat brain. Soc. Neurosci. 19:1184, 1993.

Richelson-22

99. Watson, M., Yamada, M., Yamada, Mi., and Richelson, E.: Mutations in the third cytosolic loop of the rat neurotensin receptor: effects on peptide binding and second messenger response. Soc. Neurosci. 19:1543, 1993.

100. Yamada, M., Watson, M.A., Yamada, Mi., and Richelson, E.: Lack of daily rhythmicity in neurotensin/neuromedin N mRNA levels in the medial preoptic nucleus in rat. Soc. Neurosci. 19: 100, 1993.

101. Cho, T., Yamada, M., Yamada, Mi., and Richelson, E.: Co-localization of neurotensin receptor mRNA within dopaminergic neurons. Biol. Psychiatry 35:689, 1994.

102. Yamada, M., Yamada, Mi., Cho, T., and Richelson, E.: Expression of neurotensin receptor mRNA in the brain obtained from schizophrenic patients. Neuropsychopharmacol. 10: 141S, 1994.

103. Cusack, B., Richelson, E., Pang, Y.-P., Zaidi, J., and A. Kozikowski: Pharmacological studies on novel neurotensin mimetics: discovery of a pharmacologically unique agent rationally designed according to the multiple template approach. 10th European Symposium on Structure-Activity Relationships: QSAR and Molecular Modeling. Abstracts, p. B245, 1994.

104. Yamada, M., Yamada, Mi., Watson, M.A., Groshan, K., Richelson, E.: The human neurotensin receptor is functionally nonequivalent to the homologous rat neurotensin receptor. Soc. Neurosci. 20:514,1994.

105. Yamada, Mi., Yamada, M., Cho, T., and Richelson, E.: Neurotensin receptor expression in dopaminergic neurons of the substantia nigra of post-mortem human brains. American College of Neuropsychopharmacology, Abstracts, p. 140, 1994.

106. Nakachi, N., Yamada, M., Cho, T., Coleman, N.J., Yamada, Mi. and Richelson, E.: Expression of mRNA for neurotensin in the rat brain cholinergic neurons. Biol. Psychiatry 37,642,1995.

107. Yamada, M., Yamada, M., Nakachi, N., and Richelson, E.: Apoptotic cell death induced by sodium nitroprusside in murine neuroblastoma clone N1E-115 cells. 4th IBRO World Congress Abstracts, p. 238, 1995.

108. Yamada, M., Groshan, K., Nakachi, N., Cusack, B., Yamada, M., and Richelson, E.: The expression of kappa opioid receptor mRNA in the human brain. 4th IBRO World Congress Abstracts, p. 238, 1995.

109. Yamada, M., Nakachi, N., Groshan, K., Yamada, Mi., and Richelson, E.: The expression of kappa opioid receptor mRNA in the hippocampus and the entorhinal cortex of Alzheimer's disease patient. Soc. Neurosci. 21:1623, 1995.

110. Cusack, B.M., McCormick, D., Phung, C.-T., Perry, R., Pang, Y.-P., Fauq, A., and Richelson, E.: Pharmacological profiles of newly synthesized neurotensin(8-13) analogs. Soc. Neurosci. 21:1596, 1995.

111. Zeng, X.P., Le, F., Scarisbrick, I., and Richelson, E.: Muscarinic m4 receptor agonism by atypical but not typical antipsychotics. Soc. Neurosci. 21:1707, 1995.

112. Yamada, M., Yamada, Mi., Hisamitsu, T., Uchida, N., and Richelson, E.: The use of RNA fingerprinting technique in neuropsychiatry research. Biol. Psychiatry 39,658,1996.

113. Le, F., Zeng, X.P., Groshan, K., and Richelson, E.: Organization and characterization of the human neurotensin receptor gene and its promoter region. Soc. Neurosci.22:1681, 1996.

114. Zeng, X.P., Le, F., and Richelson, E.: SR48692 discriminates between subtypes of the neurotensin receptor in human brain homogenates. Soc. Neurosci.22:2011, 1996.

115. Yamada, M., Tatsumi, M., Groshan, K., Yamada, Mi., and Richelson, E.: The pharmacological characterization of the molecularly cloned human dopamine transporter expressed in HEK cells. Soc. Neurosci. 22:1783, 1996.

116. Le, F., Zeng, X.P., and Richelson, E.: A highly informative polymorphism in the human neurotensin receptor gene on chromosome 20. Am. Soc. Human Genetics. 1996.

117. Cusack, B., Pang, Y.-P., McCormick, D., Groshan, K., and Richelson, E.: Anatomy of the neurotensin receptor: a model for drug design. Biol. Psychiatry 41:51S, 1997.

118. Tyler, B.M., Groshan, K., Cusack, C., and Richelson, E.: In vivo studies with levocabastine suggest additional neurotensin receptor subtypes. Biol. Psychiatry 41:51S, 1997.

119. Richelson, E., Souder, T., Acuna, J. and T. Chou: Binding studies with some new neuroleptics at human brain receptors. Biol. Psychiatry 41:67S, 1997.

120. Richelson, E., Souder, T., and J. Acuna: Studies on (+)- and (-)-mirtazapine at some human brain receptors. Biol. Psychiatry 41:51S, 1997.

121. Hong, F., Pang, Y.-P., Cusack, B., and Richelson, E.: Development of nonpeptidic neurotensin(8-13) mimetics. Abstracts of papers of the American Chemical Society 213: 61-Medi, Part 2, Apr. 13 ,1997.

122. Richelson, E., Cusack, B., Pang, Y.-P., McCormick, D., Groshan, K.: Neurotensin receptors in brain as targets for new neuropsychiatric drugs. Abstracts of the 6th World Congress of Biological Psychiatry, Nice, France, June 22-27, 1997. Biol. Psychiatry 42(S): 273S, 1997.

123. Tyler, B.M., Cusack, C., and Richelson, E.: A neurotensin receptor that selectively causes hypothermia. Soc. Neurosci.23:394, 1997.

124. Tyler, B.M., Richelson, E., McCormick, D.J., Fauq, A., Hoshall, C.V., Douglas, C.L., Groshan, K., Cusack, B., Lacy, B.W.: Peptide nucleic acids delivered extracranially cross the blood brain barrier. Biol. Psychiatry 43,37S,1998.

125. Cusack, B., Tyler, B.M., Fauq, A., McCormick, D.J., Lacy, B.W., Hoshall, C.V., Douglas, C.L., Groshan, K., Richelson, E.: Development of a neurotensin agonist crossing the blood brain barrier. Biol. Psychiatry 43,49S,1998.

Richelson-23

126. Groshan, K., Sobell, J., Tyler, B.M., Richelson, E.:Mutational screening of NTR-1 in schizophrenic patients by dideoxy fingerprinting. Biol. Psychiatry 43,36S,1998.

127. Hong, F., Zaidi, J., Cusack, B., Richelson, E.: Novel potent neurotensin (8-13) mimetics. Abstracts of papers of the American Chemical Society 215: 148-Medi , Part 1 Apr. 2,1998.

128. Carlier, P.R., Lo ,M.M.C., Lo, P.C.K., Richelson, E., Tatsumi, M.: Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-specific dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Abstracts of papers of the American Chemical Society 215: 154-Medi, Part 1 Apr. 2, 1998.

129. Tyler, B.M., McCormick, D.J., Jansen, K. Douglas, C.L.,Boules, M., Stables, J., Zhao, L., Lacy, B., Cusack, B., Fauq, A., and Richelson, E. :Peptide nucleic acids delivered extracranially cross the blood brain barrier and knock down gene expression. Antisense 98, Nature Biotechnology 2nd Annual Conference, London, England 1998.

130. Cusack, B., Boules, M., Fauq, A., McCormick, D., Tyler, B., and Richelson, E.: Reversal of haloperidol induced catalepsy in rats by a neurotensin agonist. Biol. Psychiatry 45: 88S, 1999.

131. Cusack, B., Boules, M., Tyler, B., Fauq, A., McCormick, D., and Richelson, E.: Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Neuropeptides at the Millennium, Abstracts. Brain Research 848:A33, 1999.

132. Tyler, B.M., Stewart, J., Jansen, K., Fauq, A., McCormick, D., and Richelson, E.: Peptide nucleic acids targeted to the dopamine transporter alter behavior. Biol. Psychiatry 47: 133S, 2000.

133. Jansen, K., Tyler, B.M., Stewart, J., Fauq, A., McCormick, D., and Richelson, E.: Pharmacokinetics of peptide nucleic acids after IV administration. Biol. Psychiatry 47: 133S, 2000.

134. Richelson, E., Cusack, B., Boules, M., Tyler, B., Fauq, A., and McCormick, D.: Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Movement Disorders 15/Supplement 3, 107, 2000.

135. Richelson, E., Cusack, B., Boules, M., Tyler, B., Fauq, A., and McCormick, D.: Novel neurotensin peptide analogs that cross the blood brain barrier as possible antipsychotic drugs: preclinical studies. Int. J. Neuropsychopharmacol. 3 (Supplement 1):S374, 2000.

136. Tyler-McMahon, B.M., Stewart, J.A., Jansen, K., Ziani-Cherif, C., Fauq, A., and Richelson, E.: Peptide nucleic acids targeted to angiotensinogen lower mRNA levels, blood pressure and angiotensin I levels in rats. Journal of Clinical Pharmacology 40:1048, 2000.

137. Katz, L.Wang, Y., Duff-Griffith, B., Tyler, B.M., and Richelson, E.: Neurotensin analog induces rapid and prolonged hypothermia after cerebral ischemia. Society of Academic Emergency Medicine, Annual meeting abstracts, p.425, 2000.

138. McMahon, B.M., Stewart, J., Jackson, J., Fauq, A., McCormick, D.J., and Richelson, E.: Antisense peptide nucleic acids targeted to the mu receptor decrease response to morphine and receptor protein levels. Biol. Psychiatry 49:49S, 2001.

139. Richelson, E., Boules, M., Warrington, L.:A brain-penetrating neurotensin analog blocks the supersensitivity to apomorphine in an animal model of Parkinson's. 41st Annual Meeting NCDEU, Phoenix, AZ, May 29, 2001.

140. Richelson, E., Boules, M., Warrington, L.: A brain-penetrating neurotensin analog blocks the supersensitivity to apomorphine in an animal model of Parkinson´s disease (PD). World Journal of Biological Psychiatry, Volume 2, Supplement 1, p. 36S, July 2001.

141. Fredrickson, P., Boules, M., Yerbury, S., and Richelson, E.: Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats. Annual meeting of the Society For Research on Nicotine and Tobacco. and Treatment, February 2002.

142. Fredrickson, P., Boules, M., Yerbury, S., and Richelson, E.: Novel neurotensin analog blocks nicotine-induced locomotor sensitization. 4th European Conference of the Society for Research on Nicotine and Tobacco (S.R.N.T.) , 2002.

143. Hedley,L.R., Secchi,R., Bingham,S., Sung,E., Richelson,E., Button, D.: The neurotensin agonist NT69L reverses dizocilpine-induced disruption of prepulse inhibition in the rat. Program No. 9.5. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. CD-ROM.

144. Shilling, P.D., Melendez, G., Richelson, E., Feifel, D.: NT69L, a neurotensin agonist, exhibits antipsychotic-like effects in the prepulse inhibition paradigm. Program No. 847.8. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2003. Online.

145. Ambrose, C., Button,D., Richelson,E., Novakovic, S.D.: Neurotensin agonist, NT69L, induces regional c-fos expression in rat brain with a pattern similar to atypical antipsychotics. Program No. 847.17. 2003 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2003. Online.

146. Wang, R., Boules, M., Gollatz, E., Tiner, W., Williams, K., Richelson, E.:Effects of 5 daily injections of the neurotensin-mimetic NT69L on dopamine release and expression of neurotensin receptors in rat. Biol. Psychiatry 55:121S, 2004.

147. Richelson, E.: Neurotensin receptor agonists: drugs for neuropsychiatric diseases. C.I.N.P. XXIVth Congress. SP48, 2004.

148. Boules, M. Fredrickson, P., Williams, K., Richelson, E.: Neurotensin receptor subtype 1 null mice are hyperactive and more sensitive to D-amphetamine. Neuropsychopharmacology 29:S186, 2004.

Richelson-24

149. Wu X, Stezoski J, Kochanek PM, Tisherman SA, Richelson E, Katz L. Neurotensin fails to augment the effect of induced mild hypothermia on survival after hemorrhagic shock in awake rats (Abstract 124). Crit Care Med 2004 Dec; 32(12 Suppl):A31.

150. Richelson E. Neurotensin receptor agonists: Drugs for neuropsychiatric diseases. Int J Neuropsychopharmacol 2004 Jun; 7(Suppl 1):S60.

151. Shaw, A.M., M. Boules, K. Williams, T.J. Paterick, P.R. Carlier, Richelson, E..: Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050 Program No. 447.8. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2005.

152. Boules, M.M., I. Iversen, A. Oliveros, A. Shaw, K. Williams, P. Fredrickson, Richelson, E.: A neurotensin agonist blocks reward and reinforcement behavior in the rat Program No. 114.15. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2005.

153. Fredrickson P, Boules M, Riley J, Baxter L, Richelson E.: Effect of an extracranially administered neurotensin analog on wakefulness (Abstract 0012). Sleep 2005; 28(Suppl):A4-A5.

154. Richelson E, Boules M, Fredrickson P. NT69L: a neurotensin receptor agonist for treatment of neuropsychiatric diseases. Neuropsychopharmacology 2005 Dec; 30(Suppl 1):S50.

155. Boules MM, Iversen I, Oliveros A, Shaw A, Williams K, Robinson J, Fredrickson P, Richelson E. A neurotensin analog attenuates intravenous nicotine self-administration in rats (Abstract 491). Biological Psychiatry. 2006;59(8):151S.

156. Shaw AM, Boules MM, Williams K, Robinson J, Carlier PR, Richelson E. Antidepressant-like effects of PRC200, a novel norepinephrine, serotonin, and dopamine reuptake inhibitor (Abstract 196). Biological Psychiatry. 2006;59(8):61S-61S.

157. Richelson E. Therapeutic neuromodulation mechanisms of action (Symposium 39, Abstract 39D). Annual meeting of the American Psychiatric Association, May 2006, Toronto, Canada.

158. Dansereau, M., A. Guillemette, G. Roussy, K. Belleville, N. Beaudet, E. Richelson, P. Sarret. Potent antinociceptive effects of NTS1 agonists in a model of neuropathic pain. Program No. 444.9. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.

159. Roussy, G., M. Dansereau, K. Belleville, N. Beaudet, E. Richelson, P. Sarret. NTS1-preferring agonists produce spinal antinociception in a formalin tonic pain model. Program No. 738.10. 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online.

160. Boules MM, Iversen I, Oliveros A, Shaw A, Williams K, Liang YQ, Fredrickson P, Richelson E. Neurotensin analogs: possible novel therapy for addiction (Abstract 6). Neuropsychopharmacology 2006; 31(Suppl 1):S199-200.

161. de Pilar Corena M, Boules M, Williams K, Oliveros A, Richelson E. Understanding metabolic networks in atypical antipsychotic drug treatment: a proteomics approach (Abstract 136). Neuropsychopharmacology 2006; 31(Suppl 1):S124.

162. Corena MDP, Boules M, Williams K, Liang YQ, Shaw A, Richelson E. Differential protein expression profiles in rat brain after treatment with mood stabilizers or with paliperidone. Biol Psychiatry 2007 Apr; 61(8 Suppl S):124S.

163. Liang Y, Boules M, Shaw A, Williams K, Fredrickson P, Richelson E. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Biol Psychiatry 2007 Apr; 61(8 Suppl S):42S.

164. Liang YQ, Oliveros A, Williams K, Boules M, Richelson E. Phosphoproteome changes after paliperidone, lithium and valproate chronic treatment: Changes in synaptoneurosomal proteins from rat prefrontal cortex (PFC). Biol Psychiatry 2008 Apr; 63(7 Suppl S):102S.

165. McLeod MDC, Nicks A, Oliveros A, Boules M, Williams K, Chaudhuri AR, Richelson E, Walss-Bass C. Clozapine and NT69L: Changes in oxidation of energy metabolism proteins in the Prefrontal Cortex (PFC) after acute injection in rats: Use of a novel proteomics approach. Biol Psychiatry 2008 Apr; 63(7 Suppl S):102S.

166. Miura T, Ceballos-Diaz C, Jansen KR, Boules MM, Williams K, Oliveros A, Liang Y, Corena M, Golde TE, Richelson E. Targeting rat NTS1 and NTS2 with shRNA-expressing adeno-associated virus (AAV). Biol Psychiatry 2008 Apr; 63(7 Suppl S):87S.

167. Oliveros A, Boules M, Brody S, Williams K, Miura T, McLeod MC, Richelson E. NT69L, a novel neurotensin analog, inhibits the acoustic startle reflex in rodent pre-pulse inhibition: Implications for use as an antipsychotic drug. Biol Psychiatry 2008 Apr; 63(7 Suppl S):106S.

168. Richelson E. Advances in the treatment of depression: Do we need to get physical? J Affect Disord 2008 Mar; 107(Suppl 1):S21.

169. Richelson E. Triple reuptake inhibitors as a new generation of antidepressant drugs. J Affect Disord 2008 Mar; 107(Suppl 1):S36.

170. Williams KD, Boules M, Cusack B, Richelson E. Application of the ProteomeLab PF 2D system and mass spectrometry for identification of proteins differentially expressed in neurotensin receptor wild type and knockout mice. Biol Psychiatry 2008 Apr; 63(7 Suppl S):90S.

Richelson-25

171. Richelson E, Fauq A, Liang Y. A novel series of triple re-uptake inhibitor potential antidepressants. Poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics, Quebec City, Canada, July 30, 2008.

172. Boules MM, Liang YQ, Oliveros A, Fauq I, Wilson M, Khaniyev S, Williams K, Barbut D, Richelson E. NT79: a novel neurotensin receptor agonist with selective behavioral effects. Biol Psychiatry 2009 Apr; 65(8 Suppl S):71S.

173. Briody S, Boules M, Oliveros A, Richelson E. NT69L: reversal of sensorimotor gating deficits, similarities to Clozapine but not Haloperidol. Biol Psychiatry 2009 Apr; 65(8 Suppl S):71S.

174. Corena McLeod M, Oliveros A, Gendron T, Gordillo Villegas A, Ceballos C, Smith K, Linser PJ, VanEkeris L, Richelson E. Cytoskeletal, synaptic and mitochondrial proteins involved in the mechanism of action of mood stabilizers. Biol Psychiatry 2009 Apr; 65(8 Suppl S):72S.

175. Li ZM, Boules M, Williams K, Peris J, Richelson E. The novel neurotensin analog NT69L blocks phencyclidine-induced increases in locomotor activity and increases in monoamine and amino acids levels in the mPFC. Biol Psychiatry 2009 Apr; 65(8 Suppl S):71S-2S.

176. Liang YQ, Boules M, Williams K, Miura T, Richelson E. Hyperactivity of dopaminergic system in neurotensin receptor null mice. Biol Psychiatry 2009 Apr; 65(8 Suppl S):71S.

177. Williams K, Boules M, Cusack B, Dugger B, Richelson E. Neurotensin subtype 2 receptor, role in obesity. A proteomic study. Biol Psychiatry 2009 Apr; 65(8 Suppl S):70S.

178. Richelson E, Oliveros A, Gordillo Villegas A, Ceballos Diaz C, Smith K, Corena-McLeod M. Mood stabilizers regulate expression and phosphorylation of mitochondrial ATP synthase and v-ATP synthase: a possible link to ph regulation. American College of Neuropsychopharmacology, 48th Annual Meeting, Hollywood, FL, December 7, 2009.

179. Corena-McLeod M, Walss-Bass C, Gordillo Villegas A, Oliveros A, Smith K, Richelson E. Mood stabilizers vs. antipsychotics: differences in mitochondrial respiration and transport. American College of Neuropsychopharmacology, 48th Annual Meeting, Hollywood, FL, December 7, 2009.

180. Boules M, Miura T, Fauq I, Oliveros A, Wilson M, Khaniyev S, Williams K, Qi Y, Katovich M, Richelson E. NT79: a novel neurotensin analog exhibiting antipsychotic-like activity without causing hypotension or hypothermia. American College of Neuropsychopharmacology, 48th Annual Meeting, Hollywood, FL, December 9, 2009.

181. Muhammad B, Patrick J, Corena-McLeod M, Richelson E, Walss-Bass C. Effects of antipsychotics and mood stabilizers on mitochondria morphology. American College of Neuropsychopharmacology, 48th Annual Meeting, Hollywood, FL, December 9, 2009.

182. Corena-McLeod M, Walss-Bass C, Gordillo Villegas A, Oliveros A, Smith K, Richelson E. Mood stabilizers vs. antipsychotics: differences in mitochondrial migration. J. Affective Disorders Volume 122, Supplement 1, April 2010, Pages S63-S64.

183. Boules MM, Li Z, Liang Y, Williams K, Richelson E. Biochemical changes in neurotensin receptor null mice: relevance to schizophrenia. Biol Psychiatry 2010;67:69S.

184. Corena–McLeod M, Gordillo A, Oliveros A, Ceballos C, Gorron N, Richelson E. differential protein expression of risperidone and paliperidone in rat pre-frontal cortex: a dose response comparison. Biol Psychiatry 2010;67:69S

185. LI Z, Boules M, Williams K, Gordillo A, Richelson E. Involvement of neurotensin receptor subtype 1 in the neuronal mechanisms of acute and chronic phencyclidine-induced schizophrenia-like signs:behavioral, neurotransmitter, and molecular studies. Biol Psychiatry 2010;67:1S-271S.

186. Corena-McLeod M, Gordillo A, Oliveros A, Ceballos C, Richelson E. Mitochondrial respiration, transport, fusion and fission: meeting high energy demands at the synapse using mood stabilizers. Biol Psychiatry 2010;67:237S.

187. Oliveros A, Heckman MG, Williams K, Boules M, Richelson E. Sensorimotor gating of neurotensin-1 receptor and neurotensin-2 receptor null mice: neurotensin-1 receptor is essential for d -amphetamine and dizocilpine induced disruption of pre-pulse inhibition. Biol Psychiatry 2010;67:265S.

188. Smith KE, Richelson E. Effect of neurotensin agonists on protein expression in the mouse brain. Biol Psychiatry 2010;67:266S.

189. Corena-McLeod M, Gorron N, Richelson E. A comparison between risperidone and paliperidone: Are these two different drugs. Poster No. 42, 2011 NCDEU 51st Annual Meeting, June 13-16, Boca Raton, Florida

190.Boules, MM, Smith K, Li Z, Shukoor N, Richelson E. Neurotensin receptor subtype 2 mediates analgesia in an animal model of persistent pain. Poster No. 582.10. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online

191.Boules MM, Cai SY, Li ZM, Shukoor N, Richelson E. NTS2 receptors: novel targets for neuropathic pain management. Biol Psychiatry. 2012 Apr 15; 71(8):302S.

192. Xiang MHA, Boules M, Richelson E. A novel mouse model for treatment of bipolar disorder. Biol Psychiatry. 2012 Apr 15; 71(8):287S.

Richelson-26

193. Boules MM, Stennett B, Li ZM, Richelson E. Novel therapy for nicotine addiction in alcoholics. Biol Psychiatry. 2013 May 1; 73(9):323S-4S.

G. PATENT APPLICATIONS GRANTED OR PENDING (I) United States Patents 1. “3-Hydroxy-propanamine derived neuronal reuptake inhibitors,” Carlier, P.R., Richelson, E., Lo, C.-K., Lo,

M.-C., U. S. Patent #6,069,177, May 30, 2000. 2. “(L) - and (D) - neo-tryptophan - A novel amino acid,” Richelson, E., Cusack, C., Pang, Y.-P., Fauq, A.,

McCormick, D., Tyler, B.M., Boules, M. U.S. Patent No. 6,214,790, April 10, 2001. 3. "Using polyamide nucleic acid oligomers to engender a biological response," Richelson, E., Tyler, B.M.,

McCormick, D.J., Cusack, B., Hoshall, C.V., Douglas, C.L., Jansen, K. U.S. Patent No. 6,472,209, October 29, 2002.

4. “Amine compounds and inhibiting neurotransmitter reuptake,” Richelson, E. and Carlier, P. U.S. Patent No. 6,700,018, March 2, 2004.

5. "Using polyamide nucleic acid oligomers to engender a biological response," Richelson, E., Tyler, B.M., Cusack, B., Douglas, C.L., Jansen, K. U.S. Patent No. 6,723,560, April 20, 2004.

6. "Using polyamide nucleic acid oligomers to engender a biological response," Richelson, E., Tyler, B.M., Cusack, B., McCormick, D.J., Hoshall, C.V., Douglas, C.L., Jansen, K. U.S. Patent No. 6,743,627, June 1, 2004.

7. “Amine compounds and inhibiting neurotransmitter reuptake ,” Richelson, E. and Carlier, P. U.S. Patent No. 6,914,080, July 5, 2005.

8. “Neo-tryptophan,” Richelson, E., Cusack, B.M., Pang,Y.-P., McCormick, D.J., Fauq, A. U.S. Patent No. 6,765,099, July 20, 2004.

9. “Neo-tryptophan,” Richelson, E., Cusack, B.M., Pang,Y.-P., McCormick, D.J., Fauq, A., Tyler, B.M., Boules, M. U.S. Patent No. 6,921,805,July 26, 2005.

10. "Using polyamide nucleic acid oligomers to engender a biological response," Richelson, E., Tyler, B.M., Cusack, B., Douglas, C.L., Jansen, K. U.S. Patent No. 6,989,270, January 24, 2006.

11. "Treating the Effect of Nicotine," Richelson, E., Fredrickson, P., Boules, M. US Patent No. 7,087,575, August 8, 2006.

12. “Neo-tryptophan,” Richelson, E., Cusack, B.M., Pang,Y.-P., McCormick, D.J., Fauq, A., Tyler, B.M., Boules, M. U.S. Patent No. 7,098,307, August 29, 2006.

13. “Amine compounds and inhibiting neurotransmitter reuptake ,” Richelson, E. and Carlier, P. U.S. Patent No. 7,214,826, May 8, 2007.

14. “Neo-tryptophan,” Richelson, E., Cusack, B.M., Pang,Y.-P., McCormick, D.J., Fauq, A., Tyler, B.M., Boules, M. U.S. Patent No. 7,642,231, January 5, 2010.

15. “Neurotensin receptor agonists and opioid receptor agonists,” Barbut, D. and Richelson, E. U.S. Patent No. 7,671,025 on March 2, 2010.

16. “Neurotensin receptor agonists and opioid receptor agonists,” Barbut, D. and Richelson, E. U.S. Patent No. 8,058,230 on November 15, 2011.

17. “Inhibiting neurotransmitter reuptake,” Richelson, E., Fauq, A. U.S. Patent No. 8,440,724, May 14, 2013. 18. “Inhibiting neurotransmitter reuptake,” Richelson, E., Fauq, A. U.S. Patent No. 8,507,500, August 13, 2013. 19. “Inhibiting neurotransmitter reuptake,” Richelson, E. Fauq, A., Carlier, P., Manceaux, CJ. U.S. Patent No.

9,944,618, April 17, 2018. Pending:

1. “Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing,” Barbut, D., Pasternak, G., and Richelson, E. U.S. Patent pending, March 12, 2008.

2. “Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2,” Richelson, E., McCormick, D.J., Pang,Y.-P.,, and Phillips, K.S. U.S. Patent pending, March 5, 2009.

3. “Neurotensin receptor agonists and opioid receptor agonists,” Barbut, D. and Richelson, E. U.S. Patent pending on November 14, 2011.

Richelson-27

(II) International Patents 1. "Using polyamide nucleic acid oligomers to engender a biological response," Richelson, E., Tyler, B.M.,

Cusack, B., Douglas, C.L., Jansen, K. Australia Patent #741246, March 14,2002. 2. “3-Hydroxy-propanamine derived neuronal reuptake inhibitors,” Carlier, P.R., Richelson, E., Lo, C.-K., Lo,

M.-C., China Patent #:ZL 98102833.0, August 25, 2004. 3. “3-Hydroxy-propanamine derived neuronal reuptake inhibitors,” Carlier, P.R., Richelson, E., Lo, C.-K., Lo,

M.-C., Hong Kong Patent #:HK1020190, May 6, 2005. 4. "Using polyamide nucleic acid oligomers to engender a biological response," Richelson, E., Tyler, B.M.,

McCormick, D.J., Cusack, B., Hoshall, C.V., Douglas, C.L., Jansen, K. Singapore Patent #72397, May 31,2005.

5. “Neo-tryptophan,” Richelson, E., Cusack, B.M., Pang,Y.-P., McCormick, D.J., Fauq, A., Tyler, B.M., Boules, M. European Patent Specification, EP 1 067 950 B1, May 14, 2008.

6. “Using polyamide nucleic acid oligomers to engender a biological response, Richelson, E., Tyler, B.M., McCormick, D.J., Cusack, B., Hoshall, C.V., Douglas, C.L., Jansen, K. European Patent Specification , EP 1 042 349 B1, August 8, 2008.

7. “Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing,” Barbut, D., Pasternak, G., and Richelson, E. European Patent Office to allow patent, March 30, 2013.